

16:30	Challenges in clinical development of stem-cell therapy <i>P. LoRusso (USA)</i>	6
-------	--	---

Wednesday, 17 November 2010

Workshop 1

Room A

Abstract number

08:00–09:45	Characterising the target for improved drug tailoring Chairs: J. Verweij (The Netherlands) and J. De Bono (United Kingdom)	
08:00	Assessing target functionality for drug and patient tailoring: a clinical perspective <i>J. Verweij (The Netherlands)</i>	7
08:25	Pharmacodynamic markers of targeted agents <i>A. Adjei (USA)</i>	8
08:50	Pharmacoeugenetics and epigenetic drugs <i>M. Esteller (Spain)</i>	9
09:15	Biosample collection in clinical trials <i>J. Hall (Belgium)</i>	10

Workshop 2

Room B

Abstract number

08:00–09:45	Pharmacogenetics and pharmacogenomics in cancer Chairs: R. Danesi (Italy) and S. Loi (Belgium)	
08:00	To genotype or to phenotype: that's the question <i>R.H.J. Mathijssen (The Netherlands)</i>	11
08:20	Pharmacogenetics of drug transporters <i>R. Danesi (Italy)</i>	12
08:40	The role of gene expression profiling in early drug development <i>S. Loi (Belgium)</i>	13
09:00	Genomic versus histological grading in soft tissue sarcomas <i>J. Coindre (France)</i>	14
09:20	Microarray and validation analyses performed on melanoma metastases identify TYRP1 as a prognostic marker for both DMFS and OS <i>G. Ghanem (Belgium)</i>	15

Workshop 3

Room C

Abstract number

08:00–09:45	European and US initiatives for early drug development Chairs: J.M. Collins (USA) and J. Blay (France)	
08:00	Molecular driven clinical trials: The EORTC Network Of Core Institutions (NOCI) Perspectives <i>D. Lacombe (Belgium)</i>	16
08:25	NCI initiatives in developmental therapeutics <i>J.M. Collins (USA)</i>	17
08:50	The Neo BIG programme <i>M. Piccart (Belgium)</i>	18
09:15	The UK Network of Experimental Cancer Medicine Centres <i>P.W.M. Johnson (United Kingdom)</i>	19

Workshop 4**Room A**

Abstract number

10:15–12:00	Rational use of targeted therapies Chairs: J. Doroshow (USA) and J. Baselga (USA)	
10:15	Re-inventing the methodology of early drug development <i>J. Doroshow (USA)</i>	20
10:40	Rational combination therapies <i>J. Baselga (USA)</i>	21
11:05	Success and pitfalls of targeted therapy combinations <i>R. Schilsky (USA)</i>	22
11:30	Targeted agents combined with radiation <i>E. Deutsch (France)</i>	23

Workshop 5**Room B**

Abstract number

10:15–12:10	Pharmacokinetics/pharmacodynamics in cancer Chairs: J. Tabernero (Spain) and M. Hidalgo (Spain)	
10:15	Factors affecting the pharmacokinetics (PK) and pharmacodynamics (PD) of nanoparticle and nanosomal anticancer agents <i>W. Zamboni (USA)</i>	24
10:40	Role of pharmacokinetics/Pharmacodynamics in dose selection of molecular targeted therapies <i>J.H.M. Schellens (The Netherlands)</i>	25
11:05	Is a side effect of molecular targeted therapy a marker of efficacy? <i>J. Tabernero (Spain)</i>	26
11:30	Drug response in a genetically engineered mouse: clinical implications <i>M. Hidalgo (Spain)</i>	27
11:55	Targeting the PI3K/mTOR pathway in genetically engineered mouse models of advanced prostate cancer <i>A. Patnaik (USA)</i>	27A

Workshop 6**Room C**

Abstract number

10:15–12:00	New drug development in the 21st century: Do we need to break from tradition? Chairs: M. Piccart (Belgium) and E. Eisenhauer (Canada)	
10:15	The point of view of academia <i>M. Piccart (Belgium)</i>	28
10:30	In search of intermediate endpoints <i>E. Eisenhauer (Canada)</i>	29
10:45	Innovation, collaboration, and agility: essential characteristics for the biopharmaceutical industry in the 21st century <i>M.L. Rothenberg (USA)</i>	30
11:00	The point of view of EMEA <i>F. Pignatti (USA)</i>	31
11:15	The point of view of FDA <i>R. Justice (USA)</i>	32
11:30	Discussion	

Special Lecture**Room A-C**

Chair: L.C. Cantley (USA)

Abstract number

14:05–14:45	Hallmarks of cancer, ten years later: evolving principles, and therapeutic targeting <i>D. Hanahan (Switzerland)</i>	33
-------------	---	----

Plenary session 2**Room A-C**

Abstract number

14:45–16:15	Proffered paper session Chairs: J. Doroshow (USA) and A. Awada (Belgium)	
14:45	Development and validation of robust immunohistochemical assays for phospho-histone-H3 and Eg5 as pharmacodynamic biomarkers to support Eg5 inhibitor (LY2523355) clinical trials in patients with advanced malignancies <i>A. Nasir (USA)</i>	1LB ¹
15:00	DNA amplifications of kinase inhibitor targets in human cancer <i>M.J. Anstett (USA)</i>	34
15:15	Mutational analysis of epithelial ovarian cancer using OncoMap <i>U. Matulonis (USA)</i>	35
15:30	Development and validation of a novel multiplexed PCR-coupled liquid bead array system for gene expression in circulating tumor cells <i>A. Markou (Greece)</i>	36
15:45	An epithelial to mesenchymal transition (EMT) gene expression signature identifies Axl as an EMT marker in non-small cell lung cancer (NSCLC) and head and neck cancer (HNC) lines and predicts response to erlotinib <i>L. Byers (USA)</i>	37

Plenary session 3**Room A-C**

Abstract number

16:30–18:30	New targets and inhibitors Chairs: L.C. Cantley (USA) and P. Schöffski (Belgium)	
16:30	The lysosomal cell death pathway <i>M. Jäättelä (Denmark)</i>	38
16:50	Update on polo-like kinase inhibitors in early clinical testing <i>P. Schöffski (Belgium)</i>	39
17:10	Metformin: What are the targets of this potential anti-cancer agent? <i>P.J. Goodwin (Canada)</i>	40
17:30	Applications of the inhibition of Mdm2 function in Cancer Therapy <i>D. Lane (Singapore)</i>	41
17:50	New inhibitors targeting critical cancer dependencies: Progress and challenges <i>P. Workman (United Kingdom)</i>	42
18:10	Targeting PI3K: where are we? <i>L. Cantley (USA)</i>	43

¹ Late breaking oral abstract, see p. 3.

Poster Sessions

Late breaking posters

	Abstract number
A first synthesis of [18F]-lapatinib: a new agent for positron emission tomographic studies of kinase receptors <i>G.L. Griffiths, F. Basuli, H. Wu, C. Li, J.L. Tatum, J.H. Doroshow</i>	4LB ²
Anti-tumor activity of MPC-9528, GMX1778 and APO866: Nampt inhibitors of three different structural classes <i>J.J. Boniface, V.R. Baichwal, L. DeMie, J.P. Green, W.R. Judd, J.W. Lockman, D.I. Papac, R.T. Terry-Lorenzo, J.A. Willardsen, R.O. Carlson</i>	5LB ³
The Nampt inhibitor MPC-9528 and the PARP inhibitor olaparib synergize in killing a BRCA-deficient cancer cell line <i>R.T. Terry-Lorenzo, T.C. Fleischer, J.W. Lockman, J.J. Boniface, J.A. Willardsen, R.O. Carlson</i>	6LB ⁴

Cancer vaccines

Poster board	Abstract number
001 Vaccination of dendritic cells pulsed with tumor endothelial cells inhibits tumor growth <i>N. Utoguchi, R. Suzuki, Y. Oda, T. Nomura, K. Maruyama</i>	44
002 Preliminary results of a phase 1 study of intravenous administration of GL-ONC1 vaccinia virus including green-fluorescent protein real time imaging in patients with advanced cancer <i>J. Vitfell-Pedersen, E.M. Karapanagiotou, S. Alam, M. Puglisi, L. Britton, S. Sassi, D. Mansfield, T. Yap, J. De-Bono, K. Harrington</i>	45
003 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors – clinical efficacy and immunological results of a phase I study <i>M.R. Wehrauch, M.S. von Bergwelt-Baildon, U. Hacker, H. Richly, U. Holtick, M. Tschaika, M. Schmidt, B. Wittig, B. Nokay, M.E. Scheulen</i>	46
004 Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors – safety results of a clinical phase I study <i>M.R. Wehrauch, H. Richly, M.S. von Bergwelt-Baildon, U. Hacker, A. Shimabukuro-Vornhagen, B. Nokay, M. Tschaika, M. Schmidt, B. Wittig, M.E. Scheulen</i>	47
005 A novel method to improve antigen presentation and immunopotency of RNA-loaded monocyte-derived dendritic cells <i>I. Tcherepanova, A. Raney, B. Martin, M. Norris, T. Monesmith, M. DeBenedette, D. Healey, F. Miesowicz, C. Nicolette</i>	48
006 A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins <i>E. Quaglino, C. Mastini, F. Riccardo, E. Ercole, M. Montani, G. Forni, F. Cavallo</i>	49

Molecular-targeted therapies – preclinical

Poster board	Abstract number
007 A phase I study of the safety, tolerability and pharmacokinetics of pazopanib (P) in combination with gemcitabine (G) for advanced solid tumors <i>H. Richly, S.D. Rubin, A. Madi, M. Jeffels, B. Nokay, D. Gibson, S. Weller, M.E. Scheulen, R. Plummer</i>	50
008 Deacetylation and inactivation of peroxiredoxin by SIRT2 increases sensitivity of breast cancer cells to oxidative stress <i>V. Coothan Kandaswamy, J. Chen, W. Fiskus, R. Rao, S. Nalluri, K. Buckley, R. Balusu, K. Bhalla</i>	51
009 Discovery of novel fused thiadiazoles as potent inhibitors of phosphoinositide-3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) <i>J. Pastor, G. Kurz, M.R. Rico Ferreira, D. Soilan, M.A. Ortega, S. Martinez, O. Rabal, I. Palacios, A. Cebria, J.R. Bischoff</i>	52

² Late breaking poster abstract, see p. 4.

³ Late breaking poster abstract, see p. 4.

⁴ Late breaking poster abstract, see p. 4.

010	Down regulation of beta-catenin by a locked nucleic acid oligonucleotide antagonist inhibits tumor growth in experimental models of human cancer <i>M. Dumble, Y. Zhang, P. Zhu, S. Kim, Z. Qu, V. Shi, J. Kearney, L.M. Greenberger, I.D. Horak</i>	53
011	Biological characterization of ETP-45299, a selective small molecule inhibitor of PIM1, in human tumor cell lines <i>C. Blanco Aparicio, A. Garcia Collazo, F. Ramos Lima, N. Ajenjo, I. Palacios, H. Quiñones, A. Rodríguez Lopez, J. Pastor, J.R. Bischoff</i>	54
012	The TORC1/TORC2 inhibitor, palomid 529 (P529), reduces tumor growth and sensitizes to chemotherapy and radiotherapy aggressive hormone refractory prostate cancer cells both in vitro and in vivo <i>C. Festuccia, G.L. Gravina, F. Marampon, L. Biordi, D. Sherri, V. Tombolini</i>	55
013	A novel interplay between Ret oncoprotein and Fap-1 controls CD95-mediated apoptosis in medullary thyroid cancer <i>V. Nicolini, G. Cassinelli, G. Cuccuru, I. Bongarzone, G. Petrangolini, M. Tortoreto, P. Mondellini, P. Casalini, F. Zunino, C. Lanzi</i>	56
014	Glioblastoma multiforme is characterized by high incidence of PDGFRalpha expression and susceptibility to the PDGFRalpha-specific antibody MEDI-575 in mouse tumor models <i>P. Steiner, L. Wetzel, M. Camara, K. Schifferli, R. Baffa, T. LaVallee, S. Coats, B. Jallal, P. Trail, Y. Chang</i>	57
015	Development and characterization of novel orally available Hypoxia-inducible factor (HIF) signaling inhibitors as dual-mechanism cancer therapeutics <i>C. Schultes, J. Alonso, A. Encinas-Lopez, B. Leber, M. Mülbaier, R. Thermann, D. Thomson, S. Wawro, B. Janssen, J. Lewis</i>	58
016	Dual targeting of mTOR and HSP90 for therapy of pancreato-biliary carcinomas <i>O. Stoeltzing, K. Staufer, H. Nagata, T.Y. Tsui, M. Jücker, B. Nashan</i>	59
017	Pre-clinical evaluation of combinations of PI3K & MEK inhibitors in colorectal carcinoma cell lines <i>E.J. Cox, S. Kyle, G.S. Beale, R.J. Maxwell, D.R. Newell</i>	60
018	Evaluation of the synthetic heat shock protein 90 inhibitors NVP-AUY922 and NVP-HSP990 in human prostate cancer tissue <i>M.M. Centenera, J.L. Treloar, A. Hanson, P. Sutherland, W.D. Tilley, L.M. Butler</i>	61
019	Pre-clinical evaluation of LYS6KAKT1, a novel, highly selective, orally bioavailable dual inhibitor of p70 S6 Kinase and AKT currently in phase I clinical trials for cancer <i>S. Geeganage, L. Sams, S. Joseph, T. Shepherd, R. Dally, L. Brail, T. Wang, A. Capen, G. Rodgers, E. Perkins</i>	62
020	Efficacy evaluation of novel Pim kinase inhibitors with anticancer activity <i>K. Brzozka, A. Zarebski, R. Windak, E. Trebacz, W. Czardybon, M. Cholody, M. Millik, N. Beuzen</i>	63
021	PDL192, a humanized antibody to TweakR exhibits potent anti-tumor activity in non-small cell lung cancer models <i>B.L. Hylander, M. Sho, S. Tanlimco, D. Choi, H. Kim, D. Chao, E.A. Repasky, K. Wilson, G.C. Starling, P.A. Culp</i>	64
022	Targeting Ras-mutated tumors with novel multiplex PI3K inhibitors through inhibition of eIF-4E-mediated protein translation <i>M. Hamilton, A.K. Bernardino, Y. Liu, K. Provoncha, D. Paul, Y. Rotshteyn, A. Han, D. Qian</i>	65
023	Tigatuzumab, a novel anti-human death receptor 5 antibody, shows synergistic efficacy against colon cancer in vitro and in vivo in combination with chemotherapy <i>A. Yada, Y. Ogitani, S. Ishida, K. Ichikawa, K. Fujiwara</i>	66
024	PTEN target therapy for glioblastoma <i>H. Kanno, S. Yamada, N. Kawahara</i>	67
025	Chemical proteomics profiling of erlotinib in NSCLC cell lines suggests novel mode of action <i>A. Augustin, J. Lamerz, S. Golling, H. Meistermann, M. Tzouros, H. Burtscher, O. Spleiss, L. Essieux, H. Langen, B. Klughammer</i>	68
026	Computational modeling and molecular optimization of stabilized alpha-helical peptides targeting NOTCH-CSL transcriptional complexes <i>R.E. Moeller, Y. Shen, O.G. Wiest, J.E. Bradner, G.L. Verdine</i>	69
027	Use of anti-VEGF therapy and antiestrogens in breast cancer cells: molecular mechanisms involved in response <i>M.A. Berciano-Guerrero, J.R. de la Haba-Rodríguez, L. López-Sánchez, V. Hernández, I. Porras, G. Pulido, A. Cañas, R. López-Pedreira, A. Rodríguez-Ariza, E. Aranda</i>	70

028	Radiosensitization by B-Raf inhibitor PLX4720 correlates with genotype status in anaplastic and differentiated thyroid carcinomas <i>T. Dasgupta, S.S. Yom, T. Sottero, X. Yang, L.A. Orloff, T.M. Jahan, D.A. Haas-Kogan</i>	71
029	Semi-rational design of β -catenin targeting peptides for the inhibition of Wnt-dependent signaling <i>T.N. Grossmann, J.T.H. Yeh, G.L. Verdine</i>	72
030	Design of a novel covalent EGFR mutant-selective inhibitor <i>R. Tjin Tham Sjin, K. Lee, M. Sheets, T.St. Martin, D. Niu, P. Chaturvedi, W. Westlin, R. Petter, M. Nacht, J. Singh</i>	73
031	Novel class I PI3K inhibitor CH5132799: disruption of the activated PI3K signaling in PIK3CA mutants confers potent antitumor efficacy <i>M. Yoshida, H. Tanaka, H. Tanimura, T. Fujii, K. Sakata, J. Ohwada, Y. Yoshimura, N. Ishii, O. Kondoh, Y. Aoki</i>	74
032	The Aurora A kinase inhibitor MLN8237 in combination with docetaxel induces synergistic antitumor activity in triple-negative breast cancer xenograft models <i>M. Zhang, J.J. Huck, M.L. Hyer, K. Kannan, S. Stroud, J.A. Ecsedy, M.G. Manfredi</i>	75
033	Design and functional analysis of a novel hybrid TPR peptide targeting Hsp90 <i>T. Horibe, M. Kohno, M. Haramoto, K. Ohara, K. Kawakami</i>	76
034	RNAi lethality screening in acute leukemias identifies weel inhibition as potent sensitizer to cytarabine and uncovers a genomic context in lymphoid malignancies <i>R. Tibes, T. Hagelstrom, J. Bogenberger, S. Arora, D. Azorsa, R. Mesa</i>	77
035	TG02, a multi-kinase inhibitor with potent single agent and chemosensitization activity against solid tumors <i>F.J. Burrows, K.C. Goh, V. Novotny-Diermayr, S. Hart, Y.C. Tan, Y.K. Loh, L.A. Cheatham, K.R. Meshaw, S. Zaknoen, J. Wood</i>	78
036	Preclinical characterization of GDC-0068, a novel selective ATP competitive inhibitor of Akt <i>K. Lin, L. Friedman, S. Gloor, S. Gross, B.M. Liederer, I. Mitchell, T. Risom, E. Punnoose, D. Sampath, N. Skelton</i>	79
037	Branched peptides as targeting agents for tumor imaging and therapy <i>J. Brunetti, C. Falciani, B. Lelli, N. Ravenni, A. Pini, L. Depau, L. Lozzi, B. Lapo, R. Moretti, L. Bracci</i>	80
038	Potential clinical application of a novel Heat Shock Protein 90 inhibitor CH5164840: preclinical efficacy in mono therapy and combination therapy <i>N. Ono, O. Kondoh, T. Yamazaki, Y. Nakanishi, A. Suda, K. Hada, R. Saito, T. Mio, N. Ishii, Y. Aoki</i>	81
039	Pharmacokinetic–pharmacodynamic modeling of the effect of GDC-0152, a selective antagonist of the inhibitor of apoptosis (IAP) proteins, on monocyte chemotactic protein-1 (MCP-1) indicates species differences in MCP-1 response <i>W. Fairbrother, H. Wong, N. Budha, B. Blackwood, S. Gould, R. Erickson, P. LoRusso, S.G. Eckhardt, A. Wagner, I. Chan</i>	82
040	Effect of TG02, a kinase inhibitor targeting Erk5, on triple negative breast cancer cells <i>M.J. Ortiz-Ruiz, L.A. Cheatham, K.R. Meshaw, F.J. Burrows, A. Pandiella, A. Esparis-Ogando</i>	83
041	Identifying statins and dipyridamole as a novel drug combination showing efficacy in multiple myeloma and acute myelogenous leukemia <i>A. Pandya, S. Sharmeen, C. Simpson, P. Boutros, A.D. Schimmer, L.Z. Penn</i>	84
042	Mechanisms underlying the therapeutic benefit of necitumumab (IMC-11F8) in combination with cisplatin/gemcitabine in NSCLC xenograft models <i>D. Deevi, S. Samakoglu, H. Li, N. Claros, S. Wang, R. Bassi, M. Prewett, J. Tonra</i>	85
043	Potent anti-tumor activity of T-DM1 antibody–drug conjugate in combination with chemotherapeutic agents in breast tumor cells <i>K. Parsons, C. Fields, B. Gunter, G. Phillips, J. Tibbitts</i>	86
044	BEZ235, a dual PI3K/mTORC inhibitor, targets the DNA damage response leading to radiosensitization and senescence <i>A. Azad, A. Natoli, S. Jackson, S.M. Maira, W. Hackl, C. Cullinane, G.A. McArthur, B. Solomon</i>	87
045	In silico and biological evaluation of correlation between efficacy of PI3K inhibitors with the activation status of signaling pathways in a panel of JFCR39 human cancer cell lines <i>S. Dan, M. Okamura, M. Seki, K. Yamazaki, M. Okui, Y. Mukai, H. Nishimura, Y. Ishikawa, T. Yamori</i>	88
046	Temozolomide treatment combined with Notch inhibition blocks recovery of glioma cells through the induction of senescence <i>C.A. Gilbert, J. Weatherbee, M.C. Daou, R.P. Moser, A.H. Ross</i>	89

047	Tivozanib activity in combination with capecitabine, 5-fluorouracil (5-FU), or docetaxel, in traditional or engineered subcutaneous breast tumor models <i>J. Lin, F. Jiang, L. Shen, M.I. Chiu, M. Robinson, E. Taguchi</i>	90
048	Identification and characterization of specific inhibitors of USP7/HAUSP deubiquitinating enzyme <i>F. Colland, C. Reverdy, S. Conrath, R. Lopez, C. Planquette, V. Collura, P. Guedat, R. Delansorne, L. Daviet</i>	91
049	The design and synthesis of a novel orally available Hsp90 inhibitor CH5164840 <i>A. Suda, H. Koyano, K. Kawasaki, N. Ono, Y. Shiratori, K. Hasegawa, T. Fukami, T. Miura, R. Saito, N. Shimma, T. Tsukuda</i>	92
050	Selective inhibition of PI3K alpha using a novel covalent compound <i>M. Nacht, L. Qiao, M.P. Sheets, T.St. Martin, M. Labenski, P. Chaturvedi, D. Niu, W.F. Westlin, R.C. Petter, J. Singh</i>	93
051	PDL192, a humanized anti-Tweak receptor monoclonal antibody, mediates antitumor effects in primary human breast carcinoma xenografts <i>L. De Plater, A. Vincent-Salomon, P.A. Culp, A. Nicolas, F. Assayag, A. Dahmani, C. Elbaz, D.T. Chao, D. Afar, D. Decaudin</i>	94
052	Therapeutic targeting the loss of the Birt–Hogg–Dubé suppresser gene <i>X. Lu, W. Wei, J. Fenton, M.S. Nahorski, E. Rabai, A. Reiman, L. Seabra, Z. Nagy, F. Latif, E.R. Maher</i>	95
053	Discovery of BMS-817378: a novel prodrug of the dual Met/VEGFR-2 inhibitor BMS-794833 <i>R. Borzilleri, J. Fargnoli</i>	96
054	In vivo anti-tumor structure–activity relationships of Judemycin C and E, small molecule modulators of the spliceosome <i>T.R. Webb, C. Lagisetti, A. Pourpak, S.W. Morris, P.M. Potter</i>	97
055	AEZS-129, an orally active PI3K inhibitor in preclinical development <i>I. Seipelt, E. Guenther, S. Baasner, L. Blumenstein, G. Mueller, J. Fensterle, J. Engel, M. Teifel, M. Gerlach</i>	98
056	Combined inhibition of EGFR and protein kinase CK2 synergistically blocks phosphorylation of ribosomal protein S6, induces apoptosis in cancer cells and displays enhanced antitumor activity in xenograft models <i>D. Drygin, J. Bliesath, A. Siddiqui-Jain, N. Huser, M. Omori, N. Streiner, C. Proffitt, C. Ho, S. O'Brien, K. Anderes</i>	99
057	Inhibition of PDGFRalpha in tumor stroma with MEDI-575 enhances activity of carboplatin/paclitaxel and delays tumor regrowth in a NSCLC xenograft model <i>P. Steiner, L. Wetzel, K. Schifferli, M. Camara, R. Baffa, T. LaVallee, B. Jallal, S. Coats, P. Trail, Y. Chang</i>	100
058	Identification of EGFR regulated genes in cetuximab resistant tumor cell models <i>M. Iida, C. Li, T.M. Brand, C.R. Peet, D.L. Wheeler</i>	101
059	Identification and preclinical characterization of NMS-P626, a potent, selective and orally bioavailable TrkA inhibitor with anti-tumor activity in a TrkA-dependent colorectal cancer <i>E. Ardini, A. Lombardi Borgia, C. De Ponti, N. Amboldi, D. Ballinari, M.B. Saccardo, P. Magnaghi, E. Pesenti, A. Isacchi, A. Galvani</i>	102
060	Combination treatment of targeting Stat3 and HIF-1alpha is a potent strategy for prostate cancer therapy <i>N. Jing, K.R. Reddy, Y.L. Guan</i>	103
061	Plasma metabolomic analysis of genetic and pharmacological manipulation of PI 3-kinase pathway activation in mice using liquid chromatography coupled to mass spectrometry (LC-MS) <i>R. Pandher, C. Ducruix, G. Box, A. Henley, M. Valenti, A. De-Haven Brandon, B. Vanhaesebroeck, P. Workman, S.A. Eccles, F.I. Raynaud</i>	104
062	BIIB024, a potent pan-Raf kinase inhibitor for melanoma and solid tumors <i>B. Elenbaas, L. Singh, A. Boccia, P. Cullen, H. Peng, E. Rohde, B. Raimundo, G. Kumaravel, I. Joseph</i>	105
063	Preclinical studies and characterization of BMS-794833, a small molecule inhibitor of Met and VEGFR-2 kinases <i>J. Fargnoli, B.J. Henley, B.S. Wautlet, R. Borzilleri</i>	106
064	Spliceosome-targeting agents modulate alternative mRNA splicing in vitro and in vivo <i>P.M. Potter, L. Fan, C. Lagisetti, C.C. Edwards, T.R. Webb</i>	107

065	Discovery of CH5132799, a novel class I PI3K inhibitor <i>J. Ohwada, H. Ebiike, H. Kawada, M. Tsukazaki, M. Nakamura, K. Morikami, K. Morita, M. Yoshida, O. Kondoh, N. Shimma</i>	108
066	Foretinib (GSK1363089) inhibits growth of gastric cancer cell lines through blockade of inter-receptor tyrosine kinases networks <i>T. Mukohara, Y. Kataoka, H. Tomioka, N. Kiyota, Y. Fujiwara, M. Yashiro, K. Hirakawa, M. Hirai, H. Minami</i>	109
067	Targeting focal adhesion kinase (FAK) in primary human schwannoma <i>M.C. Schmid, L. Zhou, S. Ammoun, C.O. Hanemann</i>	110
068	Endothelin A receptor antagonism with zibotentan (ZD4054) augments androgen ablation-induced inhibition of prostate tumor cell growth <i>B.R. Pflug, R.R. Bies, K. McHugh, J. Curwen, J.W. Growcott</i>	111
069	Targeting mTOR: a potential therapeutic approach for chondrosarcoma treatment <i>A. Dutour, A. Gougelet, A.V. Decouvellaere, T. Pointecouteau, J. Perez, J.P. Michot, J.Y. Blay</i>	112
070	Novel small-molecule inhibitors of Interleukin-6 (IL-6) signalling <i>M. Haque, G. Zinzalla, B.P. Basu, J. Anderson, S. Haider, F. Hasan, D. Antonow, D. Morgenstern, S. Neidle, D.E. Thurston</i>	113
071	The dual PI3K/mTOR blocker NVP-BEZ235 sensitizes cancer cells against irreversible ErbB inhibitors <i>T.W. Grunt, C. Br��nner-Kubath, W. Shabbir, V. Saferding, R. Wagner, C.F. Singer, P. Valent, W. Berger, C.C. Zielinski, M. Grusch</i>	114
072	Discovery and characterization of PI3Kbeta isoform-selective inhibitors <i>A. Virone-Oddos, F. Halley, C. Delorme, H. Bonnevaux, J.P. Nicolas, A. Karlsson, P.Y. Abecassis, L. Vincent, C. Lengauer</i>	115
073	R1507, a human monoclonal antibody targeting IGF-1R (insulin like growth factor receptor) is effective alone and sensitizes small cell lung cancer cell lines to chemotherapy and radiation in vitro <i>A. Gombos, Y. Lorient, J. Bourhis, J.C. Soria, K.P. Kuenkele, E. Deutsch</i>	116
074	Vorinostat induces acetylation of BH3-only gene promoters triggering their expression and leading to apoptosis in mantle cell lymphoma <i>S. Xargay-Torrent, G. Rou��, M. L��pez-Guerra, I. Saborit-Villarroya, E. Campo, D. Colomer</i>	117
075	Responses of human pancreatic tumour cells to treatment with anti-EGFR mAb ICR62 and the irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor BIBW2992 <i>N. Ioannou, A. Dalglish, A.M. Seddon, D. Mackintosh, U. Guertler, F. Solca, H. Modjtahedi</i>	118
076	ARQ 087: A potent ATP-independent fibroblast growth factor receptor (FGFR) kinase inhibitor showing in vivo anti-tumor activity in FGFR2-driven tumors <i>C.R. Chen, S. Ali, E. Nakuci, D. McSweeney, J.O. Brown, J. Szwaya, C. Bull, R. Savage, M.A. Ashwell, T.C.K. Chan</i>	119
077	Primary tumor derived preclinical model mimics human colon cancer: a novel platform to study cancer biology and to evaluate anti-cancer drugs <i>M. Sundaram, D. Pinto, B. Majumder, K. Ameer, P. Majumder</i>	120
078	Functional role of CD133 in glioblastoma multiforme <i>G. Bandopadhyay, A. Grabowska, B. Coyle, S. Watson</i>	121
079	Novel class I PI3K inhibitor CH5132799: potential clinical application in rational combination with molecular targeted therapeutics <i>H. Tanaka, M. Yoshida, H. Tanimura, T. Yamazaki, J. Ohwada, H. Ebiike, Y. Yoshimura, N. Ishii, O. Kondoh, Y. Aoki</i>	122
080	Anti-tumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action <i>A. Barnett, S. Ding, C. Murray, M. Chamberlain, S. Plummer, T.R.J. Evans, I. MacPherson, D. Bissett, C.R. Elcombe, C.R. Wolf</i>	123
081	Mechanisms of action of histone deacetylase inhibitors (HDACi) <i>A. Newbold, M. Bots, L. Cluse, R. Lindemann, S. Lowe, V. Richon, P. Secrist, T. Miller, J. Hardwick, R. Johnstone</i>	124
082	Targeting different conformations of BRAF kinase: efficacy of Omni-Raf inhibitors in NRAS and BRAF mutant tumors <i>C. Zhang, H. Cho, W. Spevak, Y. Zhang, B. Burton, B. Wong, J. Tsai, P. Ibrahim, P. Hirth, G. Bollag</i>	125

083	Impairment of S-nitrosothiol homeostasis and nitrosative stress modulate proliferation of breast cancer cells <i>A. Cañas, L.M. López-Sánchez, I. Porras, V. Hernández, G. Pulido, M.T. Cano, J.R. De la Haba-Rodríguez, C. López-Pedreira, E. Aranda, A. Rodríguez-Ariza</i>	126
084	Identification of CB3, a novel inhibitor of the ubiquitin-proteasome system <i>C. Haglund, M. Fryknäs, R. Larsson, S. Linder, L. Rickardson</i>	127
085	GDC-0941 and ABT-737 cooperate to sensitize isolated mitochondria from PI3K mutant cells <i>N. Buron, M. Porceddu, D. Disley, C. Torrance, A. Borgne-Sanchez</i>	128
086	ADAM17: A new therapeutic target for triple negative breast cancer? <i>P. McGowan, M. Mullooly, S. Sukor, N. O'Donovan, M.J. Duffy</i>	129
087	A role for the cholecystokinin 2 receptor (CCK-2R) in promoting cancer progression <i>C. Mayne, A. Grabowska, S. Watson</i>	130
088	Systematic drug combination studies with new targeted agents using 30 cell lines established from patient-derived tumor xenografts <i>G. Kelter, T. Metz, J. Fehr, M. Hiss, H.H. Fiebig, T. Beckers</i>	131
089	Intermittent dosing of the MEK inhibitor, GDC-0973, and the PI3K inhibitor, GDC-0941, results in prolonged accumulation of Bim and causes strong tumor growth inhibition in vivo <i>M. Belvin, L. Berry, J. Chan, D. den Otter, L. Friedman, K. Hoeflich, H. Koeppen, M. Merchant, C. Orr, K. Rice</i>	132
090	Role of Abcb1 (P-glycoprotein) and Abcg2 (Bcrp1) in the brain penetration of the novel PI3K Inhibitor GDC-0941 and efficacy in orthotopic xenograft models of glioblastoma and metastasis <i>L. Salphati, L.B. Lee, J. Pang, E.G. Plise, X. Zhang, M.C. Nishimura, L. Friedman, D. Sampath, H.S. Phillips</i>	133
091	Biological characterization of ETP-46321 a potent and selective phosphoinositide-3-kinase inhibitor with antitumor activity <i>J.R. Bischoff, J. Pastor, D. Cebrián, S. Martínez, M. Lorenzo, T. Merino, J. Fominaya, P. Pizcueta, A. Rodríguez Lopez, T.G. Granda</i>	134
092	Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of JNJ-26481585, a second generation histone deacetylase inhibitor <i>M.A. Smith, J.M. Maris, S.T. Keir, R.B. Lock, H. Carol, E.A. Kolb, M.H. Kang, C.P. Reynolds, I. Hickson, P.J. Houghton</i>	135
093	Activity of the Cdc7 inhibitor NMS-1116354 as single agent and in combination in breast cancer models <i>A. Montagnoli, D. Ballinari, A. Ciavolella, S. Rainoldi, M. Menichincheri, E. Pesenti, A. Galvani, A. Isacchi, J. Moll</i>	136
094	Preclinical characterization of ACTB-1010, an orally activity Aurora kinase inhibitor <i>A. Burd, L. Kunkel, A. Fattaey</i>	137
095	Combination of PI3K inhibitor BAY 80-6946 with allosteric MEK inhibitor BAY 86-9766 (RDEA119) and with erlotinib for the treatment of non-small cell lung cancer <i>N. Liu, F. Puehler, A. Haegebarth, A. Scholz, J. Hoffmann, D. Mumberg, K. Ziegelbauer</i>	138
096	Inhibition of osteolysis by CSF-1R antagonist in MM.1S orthotopic multiple myeloma model <i>S. Palakurthi, S. Grondine, N. Gingles, X. Rong, D. Lawson, P. Hall, Y. Cao, K. Wu, C. Reimer</i>	139
097	Combination of PI3K inhibitor BAY 80-6946 and allosteric MEK inhibitor BAY 86-9766 (RDEA119), a promising approach for the treatment of colorectal cancers <i>N. Liu, A. Haegebarth, F. Puehler, A. Scholz, J. Hoffmann, R. Dubowy, H. Krissel, S. Wilhelm, D. Mumberg, K. Ziegelbauer</i>	140
098	ACTB-1003 – a unique oral pan FGFR and PI3K pathway inhibitor with divergent modes of activity <i>A. Burd, M. Whiteside, J. Castillo, L. Kunkel, A. Fattaey</i>	141
099	GDC-0941 PI3K inhibitor activity in preclinical lung cancer models <i>L. Friedman, M. Belvin, L. Berry, P. Haverty, K. Hoeflich, M. Lackner, D. Sampath, J. Wallin, B. Yauch</i>	142
100	Growth response of human colorectal tumour cell lines to treatment with BIBW2992, an irreversible EGFR/HER1 and HER-2 tyrosine kinase inhibitor <i>S. Khelwatty, S. Essapen, A.M. Seddon, H. Modjtahedi</i>	143
101	Reduced expression of HER3 with a specific RNA antagonist is associated with antitumor effects in preclinical models of cancer <i>Y. Wu, R.S. Muraoka-Cook, Y. Zhang, L.M. Greenberger, C. Rinehart, C.L. Arteaga, I.D. Horak</i>	144

102	Utility of microRNA analysis for understanding treatment mechanism of action: Necitumumab +/- gemcitabine/cisplatin in NSCLC models <i>S. Samakoglu, H. Li, D.S. Deevi, J.R. Tonra</i>	145
103	Specific MET inhibition using SU11274 impairs cholangiocarcinoma cells proliferation, motility and invasion <i>C. Serrate, N. Guedj, M. Serova, D. Garbay, I. Bieche, M. Riveiro, V. Paradis, E. Raymond, S. Faivre</i>	146
104	Pharmacological characterization of NMS-P506, a novel second generation HSP90 inhibitor <i>G. Fogliatto, S. Mantegani, N. Amboldi, A. De Ponti, L. Gianellini, M. Guanci, M. Paolucci, D. Donati, E. Pesenti, A. Isacchi</i>	147
105	Therapeutic targeting of the pro-survival transcription factor CREB sensitizes glioblastomas to temozolomide-based therapy <i>J. Graff, S.H. Parsons, A.M. McNulty, M.S. Dowless, M. Phong, J. Virayah, B.W. Konicek, G. Tucker-Kellogg, L.F. Stancato, J.J. Starling</i>	148
106	Characterization of novel series of selective PI3Kalpha and PI3Kalpha/mTOR-dual inhibitors <i>P. Foster, K. Rice, J. Bussenius, C. Jaeger, L. Nguyen, A. Virone-Oddos, D. Markby</i>	149
107	Induction of endoplasmic reticulum stress by the novel anti-cancer compound KP46 and synergism with proteasome inhibition <i>J. Gojo, U. Jungwirth, P. Heffeter, B. Atil, M. Micksche, B.K. Keppler</i>	150
108	Allosteric MEK inhibitor BAY 86-9766 (RDEA119) shows anti-tumor efficacy in mono-and combination therapy in preclinical models of hepatocellular carcinoma and pancreatic cancer <i>F. Puehler, A. Scholz, M. Kissel, A. Adjei, J.N. Miner, M. Hitchcock, R. Schmieder, D. Mumberg, K. Ziegelbauer</i>	151
109	The novel highly selective and efficacious MET inhibitor BAY853474: mode of action, basic in vitro characteristics and preclinical pharmacology <i>D. Zopf, M. Kissel, M. Mamounas, K. Schuck, G. Fachinger, U. Bömer, H. Hess-Stumpp, P. Lienau, S. Ince</i>	152
110	Novel pyrazolopyrimidine derivatives as potent mTOR kinase inhibitors with anticancer activities <i>S. Chen, L. Meng, C. Liang, J. Ding</i>	153
111	Establishment and evaluation of patient-derived tumor models of adenoid cystic carcinoma: Effects of chemotherapeutics and targeted therapies on human ACC xenografts <i>F. Nieves, M. Moore, M. Mann, C. Moskaluk, A. Tolcher, K. Papadopoulos, A. Patnaik, J. Kaufman, M. Wick</i>	154
112	EML4-ALK signaling is required for the maintenance of neoplastic phenotype of non-small cell lung cancer cells: novel strategy for lung cancer tailored therapies <i>C. Voena, E. Panizza, E. Pellegrino, L. D'Amico, F.E. Boccalatte, B. Ruggeri, R.D. Polakiewicz, E. Medico, R. Chiarle, G. Inghirami</i>	155
113	DNA damage induced by camptothecins is stabilized by G-quadruplex ligands <i>C. Leonetti, M. Porru, E. Salvati, C. D'Angelo, A. Orlandi, M. Franceschin, F. Zunino, M.F.G. Stevens, A. Biroccio</i>	156
114	The mTOR kinase inhibitor AZD8055 induces cell death in Her2+ tumours partially or intrinsically resistant to ErbB2 inhibitors <i>S.V. Holt, G. Marshall, A. Logie, Z. Howard, S. Fenton, J. Dry, D. James, E. Brown, R.W. Wilkinson, S.M. Guichard</i>	157
115	3D tumour models for the assessment of tumour micro-environment targeted therapies <i>D. Onion, R. Argent, R. Kumari, S. Watson, A. Axel, B. Hall</i>	158
116	TGF- β 1 as a therapeutic target in high risk endometrial carcinomas <i>L. Muinelo-Romay, E. Colas, A. Gil-Moreno, J. Barbazán, L. Alonso-Alconada, T. Curiel, J. Cuevas, J. Reventós, R. López-López, M. Abal</i>	159
117	Cancer-associated IDH1 and IDH2 mutations: therapeutic opportunities <i>S. Jin, L. Dang, S. Gross, E. Driggers, K. Yen, M. Bittinger, C. Thompson, L. Cantley, M. Su, V. Fantin</i>	160
118	Localisation and characterisation of ET-1 binding to human colorectal cancers and evaluation of the orally active ETA receptor antagonist zibotentan (ZD4054) <i>S. Haque, M. Loizidou, X. Shiwen, D. Abraham, N. Farooqui, H. Welch, O. Ogunbiyi, J. Growcott, M. Dashwood</i>	161

119	MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations <i>S. Winski, D. Anderson, K. Bouhana, R. Impastato, R. Woessner, J. Zuzack, B. Tunquist, J. Garrus, T. Pheneger, P. Lee</i>	162
120	Effect of a novel, investigational 17,20-lyase inhibitor, TAK-700, on enzyme activity and serum androgen levels in human H295R cells and cynomolgus monkeys <i>M. Yamaoka, T. Hara, H. Miki, T. Hitaka, T. Kaku, T. Ito, N. Kawaguchi, H. Yamasaki, A. Tasaka, M. Kusaka</i>	163
121	The SEPT9_v1 first 25 amino acids fragment suppresses tumor growth through disruption of hypoxia-inducible factor 1 alpha (HIF-1 alpha) nuclear translocation <i>M. Golan</i>	164
122	JNJ-26483327, a second-generation spectrum-targeted protein tyrosine kinase inhibitor with superior characteristics in advanced cancer models <i>B. Haefner, T. Geerts, T. Lavrijssen, M. Versele, P. King, L. Andries, F. Becker, P. Carmeliet, T. Perera</i>	165
123	BAY 43-9006/Sorafenib overcomes the protective effect of stroma and synergizes with the BH3-mimetic GX15-070/Obatoclox in chronic lymphocytic leukemia cells <i>M. Lopez-Guerra, S. Xargay-Torrent, I. Saborit-Villarroya, L. Rosich, G. Roue, D. Colomer</i>	166
124	Effects of a novel, investigational 17,20-lyase inhibitor, TAK-700, on androgen synthesis in male rats: in vivo and in vitro specificity studies <i>T. Hara, M. Yamaoka, T. Hitaka, T. Kaku, A. Tasaka, M. Kusaka</i>	167
125	MiR-155 expression in acute leukemia cells treated with the multikinase inhibitor sorafenib <i>M. Goetz, C. Schult, M. Dahlhaus, K. Fischer, M. Freund, C. Junghanss</i>	168
126	Identifying molecular hallmarks of sensitivity to the anticancer effects of statins in breast tumour cells <i>C.A. Goard, M.L. Gauthier, L.Z. Penn</i>	169
127	NMS-E628, a potent and orally available small molecule inhibitor of anaplastic lymphoma kinase, reduces tumor growth in an intracranial model of ALK-dependent NSCLC <i>E. Ardini, M. Menichincheri, P. Magnaghi, C. De Ponti, N. Amboldi, A. Degrassi, M. Russo, P. Orsini, E. Pesenti, A. Galvani</i>	170
128	Amuvatinib (MP-470), a multi-targeted tyrosine kinase inhibitor and DNA repair suppressor, synergizes with etoposide (VP-16) in small cell lung cancer (SCLC) cell lines and xenografts <i>P. Taverna, L. Huang, G.S. Choy, M. Azab</i>	171
129	Molecular mechanisms of the combination treatment of cetuximab and dasatinib in Kras mutant colorectal tumors <i>E.F. Dunn, M. Iida, R.A. Myers, C. Li, D.L. Wheeler</i>	172
130	Synergistic toxicity of tyrosine kinase inhibitors with Hsp90 inhibitor 17-AAG in lung cancer cell line <i>V.L. Damaraju, M. Wilson, M. Kuzma, D. Mowles, C.E. Cass, M.B. Sawyer</i>	173
131	Investigating the role of Hedgehog signaling in tumor models <i>R.J. Austin, W. Aaron, A. Chong, M.G. Johnson, B.S. Lucas, D.L. McMinn, J. Orf, M. Rong, Q. Ye</i>	174
132	The treatment of breast cancer tumor growth and metastasis with an anti-MMP9 deoxyribozyme <i>M.A. Hallett, B. Teng, T. Seagroves, T. Sweatman, T. Pourmotabed</i>	175
133	N3-Substituted temozolomide analogs overcome methylguanine DNA methyltransferase and mismatch repair <i>T.D. Bradshaw, M. Hummersone, J. Hartley, M.F.G. Stevens, J. Zhang</i>	176
134	Amino-carbonyl substituted fused imidazoles: potent, selective and orally bioavailable inhibitors of PI3K <i>J. Pastor, S. Martínez, R.M. Álvarez, A.I. Hernández, C. Varela, A.B. García, O. Rabal, M.T. González-Granda, J. Fominaya, J.R. Bischoff</i>	177
135	Preclinical characterization of 4SC-202, a novel isotype specific HDAC inhibitor <i>S.W. Henning, R. Doblhofer, H. Kohlhof, R. Jankowsky, T. Maier, T. Beckers, M. Schmidt, B. Hentsch</i>	178
136	Allelic loss on p16, BRCA1, BRCA2, PTEN and p53 genes in sporadic invasive ductal carcinomas <i>C. Park, S. Choi, S. Cho</i>	179
137	Is sorafenib effective in colorectal cancer? <i>C. Schimanski, M.M. Markus Moehler</i>	180
138	Inhibition of erlotinib on bone metastasis of human non-small-cell lung cancer cell line NCI-H292 <i>K. Furugaki, Y. Moriya, T. Iwai, M. Yanagisawa, K. Yorozu, K. Fujimoto-Ouchi</i>	181

139	Defining efficacy thresholds in preclinical models of cancer: a comparative analysis of cetuximab efficacy and biomarkers in colorectal cancer models <i>M. Prewett, R. Bassi, K. Paz, M. Amatulli, S. Samakoglu, J.R. Tonra</i>	182
140	Amino-alkyl substituted fused imidazoles: potent, selective and orally bioavailable inhibitors of PI3K <i>J. Pastor, S. Martínez, R.M. Álvarez, C. Varela, A.I. Hernández, S. Rodríguez, J. Oyarzábal, M. Albarrán, W. Link, J.R. Bischoff</i>	183
141	Histone deacetylase inhibitor Belinostat (PXD-101) represses androgen receptor expression and acts synergistically with castration and bicalutamide treatment to inhibit prostate cancer growth hormone refractory models <i>C. Festuccia, G.L. Gravina, F. Marampon, L.A. Biordi, E. Ricevuto, C. Ficorella, V. Tombolini</i>	184
142	Anti-tumor activity of CU-201, an inhibitor of HDAC, SFK and Abl kinases <i>R. Bao, C. Lai, H. Qu, D. Wang, L. Ying, X. Tao, J. Wang, H. Zhai, H. Cai, C. Qian</i>	185
143	Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma <i>C. Li, M. Iida, E.F. Dunn, T.M. Brand, C.R. Peet, D.L. Wheeler</i>	186
144	The effect of KRAS mutations on the rectal cancer transcriptome: clinical implications <i>J. Gaedcke, M. Grade, K. Jung, J. Camps, P. Jo, H. Becker, T. Beißbarth, T. Ried, M. Ghadimi</i>	187
145	Synergistic activity of the novel apoptosis-inducing compound KP1339 with the tyrosine kinase inhibitor sorafenib in cancer cell lines of diverse origin <i>P. Heffeter, B. Atil, U. Jungwirth, E. Gal, J. Gojo, M. Micksche, B.K. Keppler, W. Berger</i>	188
146	Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers <i>N. Nechiporchik, K. Lieb, L. Marquette, L. Polin, G.J. Peters, A. Chen, S.P. Ethier, P.M. LoRusso, A.M. Burger</i>	189
147	Sorafenib effectively controls early-stage hepatocellular carcinoma but not visceral metastases in a preclinical orthotopic transplant model <i>C. Hackl, S. Man, P. Xu, R.S. Kerbel</i>	190
148	E-3810, an inhibitor of the VEGF and FGF family receptors, inhibits the FGF-dependent growth of tumor cells <i>G. Colella, G. Damia, M. D'Incalci, R. Cereda, E. Cavalletti, S. Spinelli, G. Camboni</i>	191
149	New targeted therapies strategies in hepatocellular carcinoma – In vitro studies <i>A.M. Araújo, S. Sousa Neves, A.L. Ferreira, J.D. Branco, A.B. Sarmento Ribeiro, J.M. Nascimento Costa</i>	192
150	Effects of combining amuvatinib (MP-470) with DNA-damaging agents in osteosarcoma cell lines <i>S.S. Morgan, Z.J. Wang, P. Taverna, L.D. Cranmer</i>	193
151	Characterization and preclinical development of LY2606368, a second generation Chk1 inhibitor <i>M. Marshall, C. King, D. Barnard, H. Diaz, D. Barda, A. Bence, E. Westin</i>	194
152	Molecular bases of everolimus antiproliferative activity in mantle cell lymphoma <i>L. Rosich, G. Roué, S. Xargay, M. López-Guerra, E. Campo, D. Colomer</i>	195
153	PK/PD models using a selective Ephrin B4 inhibitor JI-101 alone and in combination with other targeted agents and chemotherapy: Results of preclinical and ex-vivo studies <i>S. Sharma, R. Mullangi, M. Wade, S. Gurav, S. Sajja, D. Shankar, N. Srinivas, R. Govindarajan, L. Miller, M. Velleca</i>	196
154	AEZS-132, a new orally bioavailable PI3K/Erk inhibitor with antitumor effects <i>I. Seipelt, M. Gerlach, S. Baasner, L. Blumenstein, G. Mueller, B. Aicher, J. Engel, E. Guenther, M. Teifel</i>	197
155	Assessing the role of phosphoinositide 3-kinase (PI3K) in head and neck cancers <i>W. Shen, M. El Dinali, J. Braegelmann, J. Zoergiebel, A. Kundu, E. El-Hashani, R. Salgia, T. Seiwert</i>	198
156	Tumor colonizing bacteria – potential tumor therapy with <i>Salmonella enterica</i> serovar Typhimurium <i>K. Kochrube, S. Weiss</i>	199
157	The effect of carbohydrate- and fat-restricted diet on B16F10 melanoma model in C57BL6 mice: focus on tumor growth inhibition and its underlying molecular target signaling pathways <i>M. Choi, J. Lee</i>	200
158	Evaluation of the antitumor activity of pemetrexed in combination with the Chk1 inhibitor LY2603618 <i>M. Marshall, D. Barnard, B. Diaz, F. Feroze, L. Kays, L. Huber, V. Chen</i>	201

159	Antitumor efficacy of novel hedgehog inhibitors <i>C. Tao, S. Ci, O. D'Cruz, M. Piacente, H. Han, P. Weingarten, Q. Wang, G. Mushtaq, V. Trieu, N. Desai</i>	202
160	Perifosine in combination with antimetabolites induces synergistic effects on cytotoxicity and apoptosis in human colon, multiple myeloma, breast, renal, and liver tumor cell lines <i>B. Aicher, P. Schmidt, M. Teifel, J. Engel, E.G. Günther</i>	203
161	Effects of EGFR inhibition with tyrosine kinase inhibitors on invasive properties of EGFR mutant and wild type lung cancer cells <i>I.A. Umelo, O. De Wever, E. Teugels, M. Bracke, J. De Grève</i>	204
162	Distinct inhibitory properties of MEK inhibitors on pathway feedback translate into differential potency in BRAF and RAS mutant cancer cells <i>M. Belvin, L. Berry, J. Chan, K. Hoeflich, B. Liu, S. Malek, M. Merchant, C. Orr, K. Song, G. Hatzivassiliou</i>	205
163	The cis/trans effect of the T790M drug resistant mutation in non-small cell lung cancer <i>I. Umelo, G. Chen, E. Teugels, J. De Grève</i>	206
164	A novel selective MET inhibitor combined with erlotinib overcomes erlotinib facilitated resistance in patient derived NSCLC xenografts in vivo <i>M. Kissel, T. Müller, I. Fichtner, H. Hess-Stumpp</i>	207
165	The alkylating prodrug J1 inhibits ovarian cancer cell growth, activates proapoptotic signalling and potentiates gemcitabine responsiveness in vitro and in vivo in mice <i>K. Viktorsson, J. Gullbo, T. Juntti, M. Wickström, R. Larsson, R. Lewensohn, J. Spira</i>	208
166	Monoclonal antibody targeting of the anaplastic lymphoma kinase (ALK) receptor <i>A. Wellstein, J.J. LaConti, S.E. Kim, S. Flachmann, E. Tassi, H. Juhl, A.T. Riegel</i>	209
167	EML4-ALK is a sensitive client protein of Hsp90, and rearrangements of the ALK locus are associated with clinical response to IPI-504 (retaspimycin hydrochloride), a novel Hsp90 chaperone inhibitor, in patients with non-small cell lung cancer <i>C. Fritz, A. Lim, K. Slocum, C. Tunkey, G. Paez, K. West, R. Ross, E. Normant, L. Sequist, V. Palombella</i>	210
168	Effective therapeutic sensitization of gastrointestinal stromal tumors by a BH3 mimetic <i>T. Mühlenberg, J.A. Fletcher, F. Grabellus, M. Schuler, S. Bauer</i>	211
169	Potential therapeutic effect of oxidative stress modulators in hepatocellular carcinoma <i>A.L. Ferreira, S. Sousa Neves, A.M. Araújo, J.D. Branco, A.B. Sarmento Ribeiro, J.M. Nascimento Costa</i>	212
170	The role of MNK kinase inhibition in combination with mTOR inhibition in the proliferation of renal cancer cells <i>M. Wheeler, G. Broadley, E. Alveyn, P.W.M. Johnson, J.P. Blaydes</i>	213
171	Human ependymoma tumor-initiating cells (TICs) as a model for preclinical studies on EGFR-kinase inhibitors (EGFR-KIs) <i>D. Meco, T. Servidei, N. Trivieri, G.F. Zannoni, R. Pallini, G. Maira, R. Riccardi</i>	214
172	Anti-tumoral effects of the multi-targeted kinase inhibitor AEE788 in BRAF mutated colorectal cancer cells <i>A. Valverde, A. Gómez-España, V. Hernández, J. Jiménez, L.M. López-Sánchez, M.T. Cano, J.R. De la Haba-Rodríguez, C. López-Pedraza, A. Rodríguez-Ariza, E. Aranda</i>	215
173	Preclinical characterization of EMD 1214063 – a selective c-Met kinase inhibitor in clinical phase 1 <i>O. Schadt, D. Dorsch, F. Stieber, A. Blaukat, F. Bladt, C. Fittschen, M. Meyring, M. Friese-Hamim, C. Knuehl, U. Graedler</i>	216
174	Specific TGF-beta receptor-I inhibition using LY364947 impairs signaling, motility, and invasion in parental and multikinase inhibitor-resistant hepatocarcinoma cells <i>D. Garbay, M. Serova, C. Serrate, I. Bieche, M. Riveiro, E. Raymond, S. Faivre</i>	217
175	Down-modulation of the androgen receptor (AR) with EZN-4176 inhibits the growth of prostate tumor and potentiates the inhibitory effect of MDV-3100, a novel anti-androgen <i>Y. Zhang, S. Castaneda, S. Kim, Z. Qu, P. Kraft, M. Wang, M. Dumble, H. Zhao, L. Greenberger, I. Horak</i>	218
176	PI3K delta: Discovery of potent and selective inhibitors for treating hematopoietic malignancies <i>L. Mattheakis, P. Kearney, C. Jaeger, A. Plonowski, J. Zhang, P. Yu</i>	219

- 177 Discovery of selective inhibitors of fibroblast growth factor receptor (FGFR): Antitumor activity in cellular and xenograft tumor models with FGFR activation 220
D. Markby, M. Williams, J. Li, A. Plonowski, S. Wu, J. Loughheed, M. Ollmann

Monoclonal antibodies and targeted toxins/nuclides/agents

Poster board

Abstract number

- 178 ⁸⁹Zr-bevacizumab PET imaging in renal cell carcinoma patients: feasibility of tumor VEGF quantification 221
S.F. Oosting, W.B. Nagengast, T.H. Oude Munnink, M.N. Lub-de Hooge, A.H. Brouwers, A.W.J.M. Glaudemans, I.J. De Jong, S.J. Scherer, J.A. Gietema, E.G.E. De Vries
- 179 A first-in-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells (CSC) in patients with advanced solid tumors 222
D.C. Smith, P. Eisenberg, R. Stagg, G. Manikhas, A. Pavlovskiy, B. Sikic, A. Kapoun, S.E. Benner
- 180 Trastuzumab-DM1: mechanisms of action and mechanisms of resistance 223
G. Li, C.T. Fields, K.L. Parsons, J. Guo, G.D. Lewis Phillips
- 181 Her3 as an emerging target for lung tumor initiating cells 224
G. Ciliberto, E. Marra, Z. Gunes, A. Noto, G. Roscilli, R. Mancini, M.R. Giovagnoli, A. Ricci, E. Giarnieri, L. Aurisicchio
- 182 515H7, a novel anti-chemokine receptor 4 (CXCR4) antibody. Part II: in vivo efficacy on CXCR4-dependent tumor models 225
C. Klinguer-Hamour, F. Geronimi, B. Akla, A. Robert, C. Tardy, A. Gerentet-de-Saluneaux, J.F. Haeuw, C. Bailly, L. Goetsch, N. Corvaia
- 183 High in vivo anti-tumor activity of the immunoconjugate BT-062 against CD138 positive solid tumors 226
C. Zuber, B. Dälken, S. Aigner, T. Häder, J.A. Moreland, C.N. Carrigan, R.J. Lutz, G. Payne, F. Osterroth, C. Uherek
- 184 REGN421/SAR153192, a fully human anti-Dll4 monoclonal antibody, blocks tumor growth by reducing tumor perfusion 227
A.S. Lalani, J.R. Kirshner, C. Abrahams, A. Eichten, G. Thurston
- 185 LA480, a bivalent humanized monoclonal c-Met antibody, inhibits tumor growth through an anti-proliferative mechanism 228
L. Liu, W. Zeng, M. Wortinger, M.T. Uhlik, J. Stewart, J. Tetreault, J. Lu, P. Vaillancourt, Y. Tang, J. Wooldridge
- 186 Anti-IGF1R therapy with dalotuzumab is efficacious in a sub-set of KRAS mutant cetuximab refractory CRC models 229
S. Sathyanarayanan, D.J. Watkins, K. Sykes, S. Howard, E. Valentine, A. Bloecher, E.A. Clark, K. Hsu, D. Cunningham, C. Winter
- 187 Essential role of fibroblast growth factor receptor 2 (FGFR2) in tumorigenesis of human cancers harboring FGFR2 amplification demonstrated by a functional blocking antibody 230
A. Bai, K. Meetze, N. Vo, S. Kollipara, E. Mazsa, W. Winston, S. Weiler, L. Lerner, J. Gyuris, Z. Weng
- 188 Efficacy of VEGFR2 targeted mAb therapy in preclinical cancer models resistant to antiangiogenic therapy 231
D. Surguladze, M.J. Plym, J. Malaby, M. Prewett, M. Rutstein, J. Schwartz, D. Lu, L. Witte, J.R. Tonra
- 189 Unique molecular recognition of CD20 by the type II CD20 antibody GA101 232
G.J. Niederfellner, A. Lammens, G.J. Georges, M. Schwaiger, A. Franke, K. Wiechmann, E. Moessner, P. Umana, K.P. Hopfner, C. Klein
- 190 Engineering and characterization of a monovalent c-Met receptor Anticalin® antagonist with potent in vivo activity 233
H. Gille, A.M. Hohlbaum, K. Jensen, G. Matschiner
- 191 A phase 1, open-label, dose-finding study to assess the safety and tolerability of U3 1287 (AMG 888), a human monoclonal antibody targeting HER3 in patients with advanced solid tumors 234
P. LoRusso, V. Keedy, L. Yee, M. Oliveira, N. Rizvi, J. Berlin, X. Jin, T. Hettmann, C. Copigneaux, D. Beaupre
- 192 Negatively-charged sulfonate group in linker improves potency of antibody–maytansinoid conjugates against multidrug-resistant cancer cells 235
Y. Koutun, G. Jones, C. Audette, M. Mayo, B. Leece, R. Zhao, L. Clancy, X. Sun, R. Chari, R. Singh

- 193 Antibody–maytansinoid conjugates targeting folate receptor 1 for cancer therapy 236
O. Ab, V.S. Goldmacher, L.M. Bartle, D. Tavares, C.N. Carrigan, S. Xu, M. Okamoto, H. Johnson, K.R. Whiteman, T. Chittenden
- 194 Mechanistic pharmacokinetic/pharmacodynamic (PK/PD) modeling of xenograft tumor response of 237
Trastuzumab-DM1-antibody drug conjugates
R. Wada, H.K. Erickson, G. Lewis Phillips, C.A. Provenzano, D.D. Leipold, J. Pinkas, E. Mai, M. Gupta, H. Johnson, J. Tibbitts
- 195 Tumor penetration of therapeutic antibodies 238
J. Kendrew, A. Heier, V. Jacobs, S.D. Collins, K. McDaid, P.J. Taylor, S.T. Barry, D.C. Blakey, N.R. Smith
- 196 Paclitaxel enhances therapeutic efficacy of F8-antibody mediated delivery of interleukin-2 to 239
xenografted melanoma cancer
M. Moschetta, F. Pretto, P. Oliva, A. Bassi, P. Richter, K. Schwager, E. Trachsel, A. Berndt, D. Neri, R. Giavazzi
- 197 Molecular imaging of Death Receptor 5 (DR5) occupancy in-vivo by humanized monoclonal 240
antibody CS-1008
A.M. Scott, F.T. Lee, G.C. Cartwright, G.J. O'Keefe, R.A. Beckman, K. Fujiwara, R. von Roemeling
- 198 515H7, a novel anti-CXCR4 antibody – Part I: in vitro efficacy on CXCR4-associated signaling 241
pathways
T. Wurch, N. Boute, S. Bernois, C. Bertaux, C. Beau-Larvor, L. Troncy, C. Bailly, N. Corvaia, C. Klinguer-Hamour

Thursday, 18 November 2010

Plenary session 4

Room A-C

Abstract number

08:00–09:45	Targeting checkpoints/DNA repair in cancer Chairs: H. Calvert (United Kingdom) and H. Piwnica-Worms (USA)	
08:00	The concept of synthetic lethality <i>H. Calvert (United Kingdom)</i>	242
08:25	Targeting the Chk1/Cdc25A pathway in p53-deficient tumors <i>H. Piwnica-Worms (USA)</i>	243
08:50	PARP inhibitors <i>J. De Bono (United Kingdom)</i>	244
09:15	Targeting ATM and p53 <i>M. Kastan (USA)</i>	245

Plenary session 5

Room A-C

Abstract number

10:15–12:00	New modalities of anticancer treatment Chairs: N. Zaffaroni (Italy) and W.D. Figg (USA)	
10:15	New platforms of immunoconjugates <i>M. Sliwkowski (USA)</i>	246
10:35	Dual function BAFF receptor aptamers inhibit ligand induced proliferation and deliver siRNAs to NHL cells <i>K. Tiemann (USA)</i>	247
10:55	Targeting TRAIL receptors with genetically-engineered CD34+ stem cells <i>C. Carlo-Stella (Italy)</i>	248
11:15	The state of nanotechnology for targeted treatment delivery <i>A. Urtti (Finland)</i>	249
11:35	Targeted imaging and radionuclide therapy of somatostatin receptor positive tumours <i>F. Forrer (Switzerland)</i>	250

Special Lecture

Room A-C

Chair: J. Doroshow (USA)

Abstract number

14:05–14:45	Lessons learnt of 20 years of targeted therapies <i>A. Awada (Belgium)</i>	251
-------------	---	-----

Plenary session 6

Room A-C

Abstract number

14:45–16:15	Proffered papers Chairs: L.C. Cantley (USA) and D.A. Cameron (United Kingdom)	
14:45	Anti-tumor activity of anti-RON antibodies and biomarker of response <i>M. Han (USA)</i>	2LB ⁵
15:00	Polyclonal resistance to kinase inhibition in GIST: Mechanisms and therapeutic strategies <i>J. Fletcher (USA)</i>	252

⁵ Late breaking oral abstract, see p. 3.

15:15	Screening for PIK3CA, RAS, and RAF mutations in trials with PI3K/AKT/mTOR signaling pathway inhibitors <i>F. Janku (USA)</i>	253
15:30	cKIT overexpression and wild-type NRAS/BRAF predict response to the tyrosine kinase inhibitor dasatinib in melanoma cell lines <i>F. Journe (Belgium)</i>	254
15:45	Transcriptome sequencing of upper aerodigestive tract cancer cell lines to reveal potential therapeutic targets <i>J. Braegelmann (USA)</i>	255
15:00	MEDI-573, a dual IGF-1/-2 neutralizing antibody, blocks IGF-1R and IR-A signaling and maintains glucose homeostasis in a Phase 1 study for advanced solid tumors <i>M. Menefee (USA)</i>	3LB ⁶

Plenary session 7

Room A-C
Abstract number

16:30–18:30	Selected tumours as a niche for targeted therapies Chairs: A. Awada (Belgium) and J.-C. Soria (France)	
16:30	Emerging therapies in melanoma <i>A. Eggermont (The Netherlands)</i>	256
17:00	Recent advances in the treatment of refractory thyroid cancer: the use of kinase inhibitors <i>M. Schlumberger (France)</i>	257
17:30	Biology and treatment of thymoma <i>G. Giaccone (USA)</i>	258
18:00	Non small cell lung cancer molecular subtypes: therapeutic implications <i>J.-C. Soria (France)</i>	259

Poster Sessions

Animal models

Poster board		Abstract number
001	Multi-modality in vivo imaging of bone metabolism and tumor growth in a mouse model of bone metastasis <i>D. Lister, M. Woolliscroft, V. Kaimal, P. McConville</i>	260
002	Effects of isoflurane anesthesia on bioluminescence measurements: impact on pharmacological assessment of anti-tumor activity of chemical entities <i>C. Schnell, S. Arnal, S. Barbé, M. Becquet, C. Garcia-Echeverria, R. Cozens</i>	261
003	Establishment of patient-tumor derived xenograft models for testing anticancer agents <i>C. Liu, W.W. Li, B. Li, R. Liu, W. Zhou, W.P. Huang, F. He, C. Bai</i>	262
004	A non-invasive bioluminescent imaging technique for monitoring shutdown of the tumour vasculature <i>A.C. O'Farrell, P.A. Cooper, R.A. Falconer, M.C. Bibby, J.H. Gill, S.D. Shnyder</i>	263
005	Establishment of a targeted fluorescence guided colonoscopy for a xenograph orthotopic colorectal cancer model <i>C. Dierkes, A. Rexin, B. Wiedenmann, P. Schulz, C. Grötzing</i>	264
006	Rac1 is a therapeutic target for pancreatic cancer prevention and treatment <i>C. Lubeseder-Martellato, I. Heid, B. Sipos, S. Rieder, R.M. Schmid, J.T. Siveke</i>	265
007	Monitoring of pancreatic ductal adenocarcinoma in mouse models via multiparametric magnetic resonance imaging <i>I. Heid, M. Trajkovic-Arsic, M. Gretzinger, Y. Kosanke, A. Steingoetter, E.J. Rummeny, R.M. Schmid, J.T. Siveke, R. Braren</i>	266

⁶ Late breaking oral abstract, see p. 3.

008	Early detection of pro-apoptotic effects of chemotherapy using a caspase-3 fluorescent probe in human breast tumorgraft models <i>M.E. Legrier, H. Ligeret, C. Renauleaud, M. Lassalle, O. Déas, A. Beurdeley, S. Cairo, M. Massonneau, J.G. Judde</i>	267
009	An in vivo-like tumor stem cell-related glioblastoma in vitro model for drug discovery <i>S.S. Jensen, C. Aaberg-Jessen, A. Nørregaard, B.W. Kristensen</i>	268
010	Monitoring radiation therapy in orthotopic mouse models by bioluminescence imaging <i>M. Baugher, M. Ziemke, E. Trachet, P. McConville</i>	269
011	Human primary colon tumorgraft models possess similar clinical response characteristics <i>E.M. Bruckheimer, S.J. Strawn, M.J. Wick, F. Nieves, M. Hidalgo, D. Sidransky, E.K. Rowinsky</i>	270
012	Antitumor effect of zalypsis (PM00104) in a human pancreatic adenocarcinoma orthotopic model <i>P. Aviles, M.V. Cespedes, M.L. Soto-Montenegro, M.J. Guillén, J.J. Vaquero, P. Alamo, C. Cabrera, R. Mangues, M. Desco, C. Cuevas</i>	271
013	Humanisation of xenograft models to optimally assess the c-Met: HGF paracrine axis <i>R. Kumari, R. Argent, D. Onion, P. Clarke, S. Watson, P. King, M. Page</i>	272
014	Use of bioluminescence imaging and quantitative RT-PCR to monitor tumor progression and treatment response in orthotopic AML mouse models: Application to the targeted cytotoxic agent F14512 <i>L. Creancier, A. Pillon, J. Verdier, N. Chansard, S. Pourtau, I. Vandenberghe, C. Recher, N. Guilbaud, C. Bailly</i>	273
015	Bioluminescence imaging for monitoring tumor growth of GI-tract tumors <i>P. Schulz, C. Dierkes, A. Rexin, B. Wiedenmann, C. Grötzing</i>	274
016	A collection of patient-derived pancreatic adenocarcinoma xenografts: pharmacological and molecular characterization <i>T. Beckers, A. Maier, J. Schueler, T. Gieseemann, A. Ackermann, U. Hopt, T. Keck, I. Kohler, H.H. Fiebig, S. Kuesters</i>	275
017	Establishment and characterization of human luminal breast cancer xenografts <i>F. Assayag, P. Cottu, C. Elbaz, E. Marangoni, C. Guyader, J.J. Fontaine, A. Vincent-Salomon, F. Reyat, P. De Cremoux, D. Decaudin</i>	276
018	Preclinical antitumor assessment of bendamustine in human primary uveal melanoma xenografts <i>F. Némati, S. Piperno-Neumann, L. Desjardins, N. Karboul, C. Elbaz, A. Dahmani, X. Sastra-Garau, A. Berniard, P. Mariani, D. Decaudin</i>	277
019	Myxoid liposarcoma tumors with different chimera subtypes xenografted in nude mice are characterized by different response to trabectedin and gene expression profile <i>S. Marchini, R. Frapolli, I.F. Nerini, S. Pilotti, P. Casali, F. Grosso, R. Sanfilippo, A. Gronchi, J.C. Tercero, M. D'incalci</i>	278
020	NC-001 induces tumor growth discontinuation and necrosis in a xenograft renal cancer rat model <i>H. Hedman, L. Buvall, U. Nilsson, J. Nystrom, B. Haraldsson</i>	279
021	Bioluminescent imaging in evaluation of therapeutic strategies against cancer: Focus on orthotopic xenograft tumor models with spontaneous metastases <i>Y. Xu, E. Roschmann, O. Buiakova, D. Grass</i>	280
022	Investigation of the effect of the sequence-selective DNA cross-linking agent SJG-136 on canine tumour cells in vitro <i>M. Mellinas-Gomez, V.J. Spanswick, A. Stell, J.A. Hartley, D.E. Thurston, S. Baines</i>	281
023	Set up of a xenogenic, orthotopic and bioluminescent model of localized lung cancer in mice: a stepwise approach <i>P. Mordant, B. Lahon, Y. Lorient, Y. Castier, J.C. Soria, E. Deutsch</i>	282
024	New preclinical models of metastatic colon cancer: towards bridging the gap between bench and bedside therapeutic outcomes <i>C. Hackl, G. Francia, S. Man, P. Xu, R.S. Kerbel</i>	283
025	Establishment and characterization of individualized patient-derived low passage human tumor models: Development, validation and evaluation for clinical correlation analysis <i>V. Estrada, M. Moore, F. Nieves, K. Papadopoulos, A. Tolcher, A. Patnaik, A.J. White, R. Drengler, L. Smith, M. Wick</i>	284

- 026 Constitutive overexpression of Id-1 in mammary glands of transgenic mice results in precocious and increased formation of terminal end buds, enhanced alveologenesis, delayed involution
D.H. Shin, S.H. Jang, K.S. Jang, B.C. Kang, H.J. Kim, S.H. Oh, G. Kong 285

Clinical methodology

- | | |
|--|-----------------|
| Poster board | Abstract number |
| 027 Tailored dosing of tasisulam-sodium (LY573636-sodium) to reduce hematologic toxicity and improve therapeutic index
<i>D. de Alwis, A. Cleverly, K. Chow, I. Troconiz, R. Ilaria</i> | 286 |
| 028 Development and validation of a real-time multiplex PCR assay for the simultaneous quantification of <i>CK-19</i> , <i>MAGE-A3</i> , <i>HER-2</i> and <i>PBGD</i> in circulating tumor cells of breast cancer patients
<i>A. Strati, A. Markou, N. Malamos, V. Georgoulis, E.S. Lianidou</i> | 287 |
| 029 Pharmacokinetics and pharmacodynamics of the novel proteasome inhibitor CEP-18770 during a phase I trial in patients with solid tumor, non-Hodgkin lymphoma or multiple myeloma
<i>F. Sala, E. Marangon, D. Brunelli, C. Sessa, E. Dall'Ó, R. Cereda, V. Livi, M. D'Incalci, M. Zucchetti</i> | 288 |

Combinatorial chemistry, drug screening and synthesis

- | | |
|---|-----------------|
| Poster board | Abstract number |
| 030 3D culture systems for cancer drug evaluation
<i>M. Vinci, C. Lomas, S.M. Gowan, F. Boxall, S.A. Eccles</i> | 289 |
| 031 Novel Mcl-1 inhibitors for pancreatic cancer therapy
<i>Z. Nikolovska-Coleska, N. Bajwa, M. Liu, A. Azmi, J. Stuckey, Y. Tomita, R. Mohammad, H. Fu</i> | 290 |
| 032 Combination drug screening at the NCI
<i>S. Holbeck, M. Hollingshead, D. Newton, L. Rubinstein, J. Collins</i> | 291 |
| 033 Role of the epithelial phenotype in the sensitivity of pancreatic and breast cancer cell lines to Irvallec; in vitro synergism of the combination with gemcitabine
<i>C. Teixidó, A. Martínez, T. Moliné, R. Somoza, R. Marés, M. Aracil, J. Jimeno, L. Fernández, S. Ramón y Cajal, J. Hernández-Losa</i> | 292 |
| 034 Lithocholic acid competitively inhibits EphA2–ephrinA1 binding: pharmacological and structural considerations
<i>M. Tognolini, C. Giorgio, I. Hassan Mohamed, L. Flammini, M. Incerti, A. Lodola, E. Barocelli</i> | 293 |
| 035 Identification of NPD3483 as a unique cell division inhibitor via the cell morphology-based screen
<i>Y. Futamura, H. Osada</i> | 294 |
| 036 High throughput screening of potential anti-cancer agents in primary cell culture using an ATP based luminescence assay
<i>I.A. Cree, S. Glaysher, C. Clements, A.L. Harvey</i> | 295 |
| 037 Antitumor activity of NPD723, a novel potent cell differentiation-inducing agent in leukemic cells
<i>M. Kawatani, H. Aono, H. Osada</i> | 296 |
| 038 Design and synthesis of modified resveratrol analogues with potential apoptosis activity
<i>T.T. Htar, J.F.F. Weber</i> | 297 |
| 039 Identification of synergistic drugs using combination high-throughput screening (cHTS) and breadth of activity in diverse cancer cell networks
<i>R.J. Rickles, W.F. Tam, G.F. Short III, A. Myaskovsky, K.E. DeRoche, T.P. Giordano 3rd, B.G. Hoffstrom, P. Grossman, M.S. Lee</i> | 298 |
| 040 A new and fast in vitro screen to predict in vivo drug efficacy using cell primary culture from patient derived tumor established xenografts
<i>O. Deas, G. Stephant, E. LeVen, M.F. Poupon, J.G. Judde</i> | 299 |

Drug resistance and modifiers

- | | |
|--|-----------------|
| Poster board | Abstract number |
| 041 Novel bifunctional alkylating agents overcome multidrug resistant cancer cells
<i>T.C. Lee, P.C. Lee, R. Kakadiya, T.L. Su</i> | 300 |
| 042 Silencing of TCF7L2 sensitizes colorectal cancer cells to radiation therapy
<i>M. Grade, E. Kendziorra, K. Ahlborn, M. Spitzner, J. Gaedcke, M. Rave-Fränk, H. Becker, B.M. Ghadimi, T. Pukrop, T. Ried</i> | 301 |

043	Sulforaphane enhances effects of quercetin, sorafenib, and chemotherapy towards pancreatic cancer stem-like cells	302
	<i>I. Herr, G. Kallifatidis, V. Rausch, S. Labsch, W. Zhou, B. Baumann, J. Mattern, A.V. Salnikow</i>	
044	Hypoxia-inducible factor 1 α promotes gastric cancer chemoresistance via modulation of p53 and NF- κ B	303
	<i>N. Rohwer, C. Dame, A. Haugstetter, B. Wiedenmann, K. Detjen, C.A. Schmitt, T. Cramer</i>	
045	Anti-angiogenic therapy improves response rate in erlotinib resistant NSCLC xenografts	304
	<i>J. Rolff, I. Fichtner, M. Becker, J. Merk</i>	
046	Targeting glioblastoma stem cells: overcoming temozolomide resistance by ALDH1 inhibition	305
	<i>A. Schaefer, J. Teufel, M. Rasper, I. Hoepner, F. Ringel, J. Schlegel</i>	
047	The selective reduction in the production of Bmi-1 protein leads to tumor growth control in multiple tumor models	306
	<i>T.W. Davis, L. Cao, N. Sydorenko, K. Medvigy, J. Sheedy, N. Risher, M. Weetall, Y.C. Moon</i>	
048	An antisense molecule to HER3 sustains growth inhibitory effects in gefitinib resistant cells that are independent of MET overexpression	307
	<i>Z. Qu, Y. Wu, Y. Zhang, P. Zhu, V. Shi, M. Wang, S. Kim, P. Kraft, L. Greenberger, I.D. Horak</i>	
049	Internalization systems of EGFR could affect the efficacy of gefitinib in NSCLCs with wild-type EGFR	308
	<i>U. Jo, J.S. Sung, H.Y. Jung, K.H. Park, H.N. Jung, Y.M. Whang, Y.H. Kim</i>	
050	Potentiating the anti-tumor efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor signaling pathway	309
	<i>D. Ou, C. Hsu, Y.T. Huang, Y.C. Shen, B.S. Lee, A.L. Cheng</i>	
051	Acquired resistance to HSP90 inhibitor and cancer progression	310
	<i>R.C.C. Chai, J.L. Vieusseux, C.H. Nguyen, B.J. Lang, M.M. Kouspou, J.T. Price</i>	
052	MAGEA tumour antigens mediate platinum cytotoxicity in NSCLC	311
	<i>E.S.R. Collie-Duguid, J.D. Bissett, R.D. Petty, M.C. Nicolson, K. Kerr, L. Cao</i>	
053	MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors	312
	<i>E. Ghiso, V. Cepero, J.R. Sierra, S. Corso, L. Casorzo, T. Perera, P.M. Comoglio, S. Giordano</i>	
054	Resistance to the microtubule-stabilizing agents, peloruside A and laulimalide, is associated with multiple β -tubulin alterations	313
	<i>A. Kanakkanthara, J. Crawford, P. Rawson, B. Kivell, P.T. Northcote, J.H. Miller</i>	
055	Acceleration of migration mediated by Insulin-like Growth Factor-1 receptor and Syk kinase in bortezomib-resistant myeloma cells	314
	<i>Y. Terui, Y. Mishima, K. Hatake</i>	
056	The corepressor-associated protein Tab2 as a new target to revert resistance to antiestrogens in breast cancer	315
	<i>S. Reineri, S. Cutrupi, A. Panetto, L. Ricci, A. Lykkesfeldt, M. De Bortoli</i>	
057	The gastric modifier esomeprazole did not affect the bioavailability and tolerability of CS-7017 in an open-label, phase I, two-way crossover clinical study in healthy subjects	316
	<i>R. Schever, H. Zahir, R. Luo, L. He, R. Noveck, K. Liu</i>	
058	Activation of the endothelin signaling pathway is linked with acquisition epithelial–mesenchymal transition phenotype of chemoresistant ovarian cancer cells	317
	<i>L. Rosanò, R. Cianfrocca, V. Di Castro, F. Spinella, A. Lucidi, G. Ferrandina, P.G. Natali, A. Bagnato</i>	
059	Changes in the transcription regulation mediated by FUS-CHOP gene in a myxoid liposarcoma cell line resistant to trabectedin	318
	<i>S. Ubaldi, S. Bernasconi, M. Romano, S. Marchini, S. Di Giandomenico, G. Damia, M. Ganzinelli, C.M. Galmarini, E. Erba, M. D'Incalci</i>	
060	Tumour hypoxia and ALDH expression may contribute to reduced response to therapeutic agents in HNSCC cell lines	319
	<i>M. Zimmermann, C. Box, P. Rhys-Evans, K.J. Harrington, S.A. Eccles</i>	
061	Enhancement of 5 fluorouracil (5FU)-mediated cytotoxicity in human gastric cancer (GC) cells by the phosphatidylinositol 3-kinase (PI3K) inhibitor, PI103, via thymidylate synthase (TS) inhibition	320
	<i>B. Bhattacharya, M. Akram, I. Balasubramanian, R. Soong</i>	
062	Oleanolic acid derivative methyl 3-hydroxyimino-11-oxoolean-12-en-28-oate inhibits ABCC1/MRP1 protein function and reduces its level in acute promyelocytic leukemia cells	321
	<i>A. Paszel, B. Bednarczyk-Cwynar, L. Zaprutko, J. Hofmann, M. Rybczynska</i>	
063	Iron chelators that overcome drug resistance	322
	<i>T. Yamagishi, P.J. Jansson, D.R. Richardson</i>	

064	Targeting the MAPK pathway to increase sensitivity of ovarian carcinoma cells to platinum compounds <i>G. Cossa, C. Lanzi, L. Gatti, G.L. Beretta, G. Cassinelli, N. Carenini, L. De Cecco, S. Canevari, F. Zunino, P. Perego</i>	323
065	Mechanisms associated with Sunitinib-resistance in human breast carcinomas <i>M. Riveiro, M. Serova, S. Albert, G. Bousquet, M. Sablin, I. Bieche, A. Janin, E. Raymond, S. Faivre</i>	324
066	Food does not affect the pharmacokinetics of CS-7017 in healthy subjects: results from an open label, phase I, two-treatment, three-period, crossover study <i>R. Scheyer, H. Zahir, R. Luo, L. He, R. Noveck, K. Liu</i>	325
067	Co-administration of a CYP3A4 inhibitor (ketoconazole) increased the bioavailability of CS-7017 but did not affect tolerability: results from an open-label, phase I, two-way crossover study in healthy subjects <i>G. Senaldi, H. Zahir, L. He, J.C. Rasmussen, K. Liu, R. Scheyer</i>	326
068	Activating transcription factor 3 as a novel regulator and predictor of cisplatin response in human cancers <i>A. O'Brien, J. Dimitroulakos</i>	327
069	P-glycoprotein antagonists as opposed to inhibitors of glucosylceramide synthase enhance short-chain ceramide cytotoxicity in human ovarian cancer cells <i>J.V. Chapman, V. Gouazé-Andersson, R. Karimi, M.C. Cabot</i>	328
070	Insights into the cellular responses against different DNA-binding agents <i>M. Zihlif, L. Wakelin, D. Catchpool, B. Bernard W. Stewart</i>	329
071	P-glycoprotein in doxorubicin resistant MCF-7 breast cancer cells: DPAGT1 approach to N-glycosylation regulation <i>I. Kuznecovs, G. Kuznecova, K. Jegina, S. Kuznecovs</i>	330

Drug targets

	Poster board	Abstract number
072	Atrimers as a novel class of potent trimeric therapeutics inducing cancer cell death <i>A. Kretz Rommel, M. Renshaw, E. Chen, R. Ferrini, D. Oltean, G. Batzer, J. da Silva, B. Lin, W. Zhu, K. Bowdish</i>	331
073	POLQ (DNA polymerase theta) as a novel therapeutic target: preclinical and clinical data <i>G.S. Higgins, R. Prevo, C. Lundin, T. Helleday, F.M. Buffa, A.L. Harris, R.J. Muschel, E.J. Bernhard, I.D. Hickson, W.G. McKenna</i>	332
074	Identification of drug-associated proteins in NSCLC xenograft models by reverse phase protein arrays <i>H. Hülsmann, C. Bender, J. Rolff, I. Fichtner, R. Herwig, H. Sülthmann, R. Kuner</i>	333
075	Tropomyosin Tm5NM1: A novel target for cancer therapy <i>J. Stehn, G. Schevzov, T. Bonello, A. McCluskey, N. Haass, S. Palmer, E. Hardeman, M. Allanson, V. Reeve, P. Gunning</i>	334
076	CD133+ or CD44+CD166+ cells from human colorectal cancer cell lines do not display cancer stem-cell features nor increased drug resistance <i>M.G. Muraro, V. Mele, J. Han, G.C. Spagnoli, G. Iezzi</i>	335
077	Splicing factors as novel therapeutic targets in ovarian and breast cancers <i>W. Beck, X. He, A.D. Arslan, T.T. Ho, N. Mahmud, M.D. Pool, J.S. Coon</i>	336
078	Differential action of ErbB kinase inhibitors on receptor oligomerization <i>M. Sanchez-Martin, A. Pandiella</i>	337
079	Preclinical profile of novel and potent c-Met kinase inhibitors <i>S. Vakkalanka, M.P. Muthuppalaniappan, G. Babu, S. Kuppireddi, S. Viswanadha, S. Veeraraghavan, K.K.V.S. Varanasi</i>	338
080	Fibroblast growth factor receptor 4 (FGFR4) G388R polymorphism in colorectal cancer <i>C. Heinzele, M. Hunjadi, Z. Erdem, S. Stättner, M. Klimpfner, B. Grasl-Kraupp, K. Holzmann, M. Grusch, W. Berger, B. Marian</i>	339
081	Inhibition of aldehyde dehydrogenase (ALDH) reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ breast cancer cells <i>A. Croker, A.L. Allan</i>	340
082	Targeting NEK2 kinase in drug resistant multiple myeloma with small molecule inhibitors <i>B. Stephens, F. Xiao, M. Zangari, H. Xu, G. Tricot, F. Zhan, A. Mollard, H. Vankayalapati, S. Sharma, D. Bearss</i>	341

083	Characterization of cancer cell killing mechanisms of targeted hybrid peptide that binds to transferrin receptor <i>M. Kawamoto, T. Horibe, M. Kohno, K. Kawakami</i>	342
084	Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of squamous NSCLC cells <i>K. Hoeflich, C. Ong, A. Jubb, P. Haverty, T. Truong, A. Harris, M. Belvin, L. Friedman, E. Blackwood, H. Koeppen</i>	343
085	Pharmacological and pharmacokinetic profile of AI1008, a novel and potent inhibitor of abl-kinase activity <i>R. Desai, G.S. Merikapudi, K.K.V.S. Varanasi, S. Viswanadha</i>	344
086	Preclinical profile of novel, potent, and selective PI3 kinase delta inhibitors <i>S. Viswanadha, M.P. Muthuppalaniappan, K.V.V.S. Varanasi, G. Babu, R.R. Lekkala, S. Veeraraghavan, S. Vakkalanka</i>	345
087	Activated RON tyrosine kinase drives cellular proliferation, migration and invasion with corresponding tumor growth and metastasis in mice <i>M.R. Albertella, Y. Peng, S. McCormack, J. Kahler, S. Thomson, D. Landfair, P.C. Gokhale, J.E. Bugaj, R. Wild, J. Pachter</i>	346
088	Blockade of fatty acid synthase causes ubiquitination and degradation of PI3K effector proteins in ovarian cancer <i>T.W. Grunt, H. Karlic, R. Wagner, C.F. Singer, F. Varga, K. Tomek</i>	347
089	Targeting pancreatic cancers with a G-quadruplex binding small molecule <i>S.M. Hampel, M. de la Fuente, A. Schatzlein, A. Sidibe, J.F. Riou, S. Neidle</i>	348
090	Monocarboxylate transporter 1 as a potential therapeutic target in glioblastomas <i>V. Gonçalves, C. Pinheiro, M. Honavar, P. Costa, R. Reis, F. Baltazar</i>	349
091	Target therapy and endoarterial chemotherapy with ozonotherapy in combined treatment of metastatic colorectal cancer <i>E.T. Akbarov, S.N. Navruzov, S.B. Abdujapparov, H.D. Islamov</i>	350
092	Inhibition of monocarboxylate transporter 1 in cervical cancer cells: effect of alpha-cyano-4-hydroxycinnamate and siRNA <i>C. Pinheiro, S. Pinheiro, E. Bocardo, A.P. Lepique, A. Longatto-Filho, L.L. Villa, F. Baltazar</i>	351
093	Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) mediated signaling and anaplastic large cell lymphoma growth <i>L. Riera, E. Lasorsa, C. Ambrogio, N. Surrenti, C. Voena, R. Chiarle</i>	352
094	Integrating alternative splicing studies as a tool for innovative therapeutical interventions: focus on novel drug targets and novel epitopes <i>A. Casagrande, M. Pando, L. Desire</i>	353
095	Investigations on organic anion-transporting polypeptides 1A2, 1B1 and 1B3 in colon cancer as potential targets for cancer therapy <i>V. Kounnis, E. Ioachim, M. Svoboda, I. Sainis, C. Ausch, G. Hamilton, T. Thalhammer, E. Briasoulis</i>	354
096	Identification of an inhibitor for melanoma cell migration through the inhibition of Pirin <i>I. Miyazaki, S. Simizu, H. Osada</i>	355
097	An innovative platform technology accelerates drug screening <i>F. Becker, S. Hannus, K. Hansen</i>	356
098	Antitumor triazoloacridinone C-1305 as a potent FLT3 tyrosine kinase inhibitor in human acute myeloid leukemia (AML) cells <i>E. Augustin, A. Skwarska, J. Koprowska, I. Pelikant, J. Konopa</i>	357
099	Study of cetuximab and panitumumab activity in an 80 cell line panel to evaluate specificity of small molecule EGFR inhibitors <i>I. Ivanov, P. Amon</i>	358
100	Effect of the TGF-beta2 specific antisense oligodeoxynucleotide trabedersen on TGF-beta2 and -beta1 expression in human glioma cells: Cross-regulatory loops regulate TGF-beta isoform expression <i>F. Jaschinski, M. Kielmanowicz, T. Rothhammer, A. Schneider, K.H. Schlingensiepen</i>	359
101	BIO, the GSK3 beta blocker, is a potent inhibitor of cell proliferation and inducer of cell death of cervical carcinoma and rhabdomyosarcoma tumor cells <i>M. Majka, W. Bobela, K. Miekus</i>	360

- 102 HGF regulates the activity of GSK3 in rhabdomyosarcoma cells 361
M. Majka, K. Miekus, W. Bobela

Molecular-targeted therapies – clinical trials

Poster board

Abstract number

- 103 First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers 362
R.M. Wenham, S.K. Sandhu, G. Wilding, L. Sun, C. Toniatti, M. Stroh, C. Carpenter, J. de-Bono, R. Baird, W.R. Schelman
- 104 Dose of the molecularly targeted agents (MTA) in Phase 1 trials correlates with clinical benefit 363
S. Gupta, A. Alqwasmi, S. Hunsberger, L. Rubinstein, P. Ivy, R. Royds, P. LoRusso
- 105 The first-in-human, first-in-class study of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR, and HER2: A Phase I study in patients with advanced cancer 364
T. Shimizu, A.W. Tolcher, P. LoRusso, K. Papadopoulos, A. Patnaik, L. Smith, M. Keegan
- 106 First-in-human, safety, pharmacodynamic (PD) and pharmacokinetic (PK) trial of a first-in-class dual RAF/MEK inhibitor, RO5126766, in patients with advanced or metastatic solid tumour 365
J.C. Soria, U. Banerji, R. Bahleda, M. Martinez Garcia, S. Dolly, L. Lee, R. Rueger, E. Guarin, V. Meresse, J. Albanell
- 107 A Phase 1 study of continuous dosing with PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase 366
A. Jimeno, R.S. Herbst, G.S. Falchook, W.A. Messersmith, D.R. Camidge, S.R. Peterson, D.F. Hausman, R. Kurzrock, S.G. Eckhardt, D.S. Hong
- 108 A first-in-human Phase 1 study of anti-CD105 antibody therapy with TRC105 in patients with advanced solid tumors 367
L. Rosen, M.S. Gordon, H.I. Hurwitz, M.K. Wong, J. Goldman, B.J. Adams, D. Alvarez, B.K. Seon, C.P. Theuer, B.R. Leigh
- 109 A multi-center Phase 1, dose-escalation trial to determine the safety and pharmacokinetics/pharmacodynamics of BAY 86-9766 (RDEA119), a MEK inhibitor, in advanced cancer patients 368
C. Weekes, D.D. Von Hoff, A.A. Adjei, L. Yeh, D. Leffingwell, B. Sheedy, C. Iverson, P. Rajagopalan, R. Dubowy, N. Clendeninn
- 110 Timing of responses to crizotinib (PF-02341066) in anaplastic lymphoma kinase (ALK)-positive patients with advanced non-small cell lung cancer (NSCLC) 369
B. Solomon, Y.J. Bang, D.R. Camidge, A.J. Iafrate, E.L. Kwak, R.G. Maki, S.I. Ou, R. Salgia, A. Shaw, J. Clark
- 111 A phase Ib study of escalating doses of Vascular Endothelial Growth Factor (VEGF) tyrosine kinase inhibitor Tivozanib and FOLFOX6 in patients with advanced gastrointestinal (GI) tumors 370
F. Eskens, C. Oldenhuis, P. Bhargava, W. Loos, B. Esteves, L. van Doorn, M. Cotreau, R. Dillon, J. Gietema, E. de Vries
- 112 Phase 2 randomized discontinuation trial (RDT) of XL184 in patients (pts) with advanced solid tumors 371
P. Schöffski, M. Sgroi, H.A. Burris, J. Lutzky, T. Rearden, B. Sikic, J. Stephenson Jr., D. Elhardt, Y. Lee, R. Kurzrock
- 113 A phase I dose-escalation study of the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously to patients with advanced solid tumors 372
C. Weekes, P. Hedge, Y. Xin, R. Yu, H. Xiang, L. Gore, M. Beeram, R. Brachmann, A. Patnaik
- 114 The oral MEK1/MEK2 inhibitor, GSK1120212, effectively inhibits the MAPK pathway: pharmacokinetic, pharmacodynamic, and clinical response relationship 373
M.S. Gordon, J.R. Infante, W. Messersmith, L.A. Fecher, N.J. Vogelzang, D. Cox, D.J. DeMarini, Y. Xu, V. Peddareddigari, G. Falchook
- 115 Clinical, pharmacokinetic (PK) and pharmacodynamic (PD) results of first-in-man phase I trial of the orally available MEK-inhibitor MSC1936369 (AS703026) in patients (pts) with advanced solid tumors 374
A. Awada, N. Houedé, J.P. Delord, M. Dubuisson, A. Italiano, Y. Bergé, S. Faivre, A. Taama, C. Lüpfer, E. Raymond

116	A Phase 1 dose escalation study of the oral heat shock protein 90 (Hsp90) inhibitor PF-04929113/SNX-5422 (PF-113) and its associated ocular toxicity <i>J. Infante, G. Weiss, S. Jones, R. Tibes, J. Bendell, N. Brega, V. Torti, D. Von Hoff, H. Burris III, R. Ramanathan</i>	375
117	Preliminary results from a Phase 1 study of D-3263 HCl, a TRPM8 calcium channel agonist, in patients with advanced cancer <i>A. Tolcher, A. Patnaik, K. Papadopoulos, T. Mays, T. Stephan, D.J. Humble, M.W. Frohlich, R.B. Sims</i>	376
118	A phase 1, dose-escalation, safety, pharmacokinetic and pharmacodynamic study of PF-03732010, an IgG1 monoclonal antibody against P-cadherin (placental), administered to adult patients with advanced solid tumors <i>Y. Bang, R. Cohen, T. Blumenkopf, Y. Zhang, M. Toh, A. Countouriotis, D. Shalinsky, S. Zhang, J. Gallo, J. Desai</i>	377
119	Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive endometrial cancer. Protocol AGO-GYN 5, AGO Study Group, Germany <i>G. Emons, J. Sehouli, G. Gorchev, A. Hristamian, A. Staehle, L.C. Hanker, P. Wimberger, M.W. Beckmann, V. Taskova, C. Gruendker</i>	378
120	A first in human phase I study of the proteasome inhibitor CEP-18770 in patients (pts) with advanced solid tumors, non-Hodgkin's lymphomas (NHL) and multiple myeloma (MM) <i>C. Sessa, G. Martinelli, D. Hess, A. Delmonte, C. Noberasco, S. Sammassimo, E. Gallerani, S. Marsoni, G. Camboni, F. de Braud</i>	379
121	Phase I trial of OXi4503: positron emission tomography (PET) analysis shows early effects on tumour perfusion that predict metabolic response <i>P. Price, M.C. Asselin, B. Kotz, N. Charnley, G. Watkins, G.J.S. Rustin, J. Balkissoon, Z. Goldberg, C. Drug Development Office, A. Saleem</i>	380
122	Preliminary results of a dose escalation study of the Fibroblast Growth Factor (FGF) "trap" FP-1039 (FGFR1:Fc) in patients with advanced malignancies <i>A. Tolcher, K. Papadopolous, A. Patniak, E. Heath, A. Weise, T. Prokop, S. Morrone, J. Zanghi, H.N. Keer, P. LoRusso</i>	381
123	Influence of rosuvastatin on the pharmacokinetics of imatinib: a cross-over study <i>K. Eechoute, R.M. Franke, W.J. Loos, P. de Bruijn, J. Verweij, A. Sparreboom, R.H.J. Mathijssen</i>	382
124	First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics <i>C.D. Britten, A.A. Adjei, R. Millham, B. Houk, Z.A. Wainberg, T. Guthrie, G. Dy, P.M. LoRusso</i>	383
125	Phase 1/2 trial of CF102, a selective A3 adenosine receptor (A3AR) agonist, in patients with hepatocellular carcinoma (HCC) <i>S. Stemmer, M.H. Silverman, W.D. Kerns, S. Bar Yehuda, S. Fishman, Z. Harpaz, M. Farbstein, O. Binyaminov, G. Medalia, P. Fishman</i>	384
126	A first in human phase 1 study of the safety and pharmacokinetics of a novel Cdc7 inhibitor NMS-1116354, administered orally to patients with solid tumors <i>K. Papadopoulos, S. Crippa, A. Hanssen, A. Montagnoli, F. Fiorentini, A.W. Tolcher, M. Martignoni, A. Isacchi, B. Laffranchi, A. Patnaik</i>	385
127	Phase I study of the vascular disrupting agent (VDA) ombrabulin (Ob) in combination with taxanes (T) and platinum salts (PS) in patients (pts) with advanced solid tumors <i>J.C. Soria, R. Bahleda, B. Besse, C. Sessa, R.g. Calderone, L. Gianni, G. Del Conte, A. Perotti, B. Daglish, C. Oprea</i>	386
128	First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics <i>G.I. Shapiro, J. Molina, J. Bendell, I. Braña, J. Spicer, E. Kwak, S. Pandya, R. Millham, B. Houk, K. Bell-McGuinn</i>	387
129	Imetelstat sodium (GRN163L), a telomerase inhibitor: tolerability, pharmacokinetics and pharmacodynamic activity using an intermittent once every four weeks dosing schedule in patients with advanced solid tumors <i>M.J. Ratain, S. Kelsey, L. Janisch, J. Smith, N. Go, T. Lin, M.L. Maitland, H.L. Kindler, P.M. LoRusso</i>	388
130	A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTor inhibitor GDC-0980 administered QW <i>A.J. Wagner, G.C. Jayson, C. Gomez-Roca, Y.K. Zee, J.A. Morgan, Y. Yan, J. Ware, K.E. Mazina, J. Lauchle, J.C. Soria</i>	389

- 131 TH-302, a tumor selective hypoxia activated prodrug, complements and enhances chemotherapy treatment with gemcitabine, docetaxel, pemetrexed, and doxorubicin 390
C.P. Hart, M. Borad, S.P. Chawla, J.R. Infante, K.N. Ganjoo, V.K. Langmuir, S. Kroll, J.G. Curd
- 132 A phase I clinical trial of CXR1002 in patients (pts) with advanced cancer 391
M. Macpherson, D. Bissett, B. Tait, L.M. Samuel, J. MacDonald, A.L. Barnett, C.R. Wolf, C.R. Elcombe, A. Jeynes-Ellis, T.R.J. Evans
- 133 A phase IA, dose-escalating study of LBH589 administered intravenously in adult patients with advanced solid tumors 392
S. Oizumi, Y. Ando, K. Kitagawa, S. Morita, Y. Komatsu, S. Yuki, Y. Fujiwara, N. Kiyota, K. Kobayashi, H. Minami
- 134 Phase I pharmacokinetics and pharmacodynamics of GDC-0152, a novel IAP protein antagonist, administered to patients with locally advanced or metastatic malignancies 393
W. Fairbrother, P. LoRusso, A. Wagner, N. Budha, W. Darbonne, Y. Shin, H. Wong, I. Chan, J. Ware, S.G. Eckhardt
- 135 A phase I dose escalation and pharmacological study of the novel class I selective histone deacetylase inhibitor CHR-3996, in patients with advanced or treatment refractory solid tumours 394
F. Eskens, L. van Doorn, D. Papadatos-Pastos, P. Debnam, M. Tall, M. Toal, L. Hoofman, J. Verweij, U. Banerji
- 136 MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor, in combination with erlotinib: clinical and preclinical experience 395
A. Patnaik, J. Besterman, A.W. Tolcher, M. Mehran, M. Drouin, C. Maroun, C. Bonfils, M. Beeram, R. Martell, K. Papadopoulos
- 137 MGCD265, an orally active Met/VEGFR multitargeted kinase inhibitor, in combination with docetaxel: clinical and preclinical experience 396
P. O'Dwyer, K. Papadopoulos, R. Amaravadi, K. Harlackner, M. Beeram, M. Drouin, M. Mehran, J. Besterman, C. Maroun, A. Patnaik
- 138 Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC) 397
C. Yaseenchak, K. Nackaerts, A. Awada, S.M. Gadgeel, B. Hellerstedt, M.C. Perry, D. Richards, C.H. Yang, C. Scheffold, P.N. Lara Jr.
- 139 Phase 2 results of XL184 in a cohort of patients (pts) with advanced melanoma 398
H. Nechushtan, G. Edelman, G. Jerusalem, M. Gordon, H.M. Kluger, A. Moussa, I. Ron, F. Schimmoller, X. Shen, A. Daud
- 140 Why is rapamycin effective against Kaposi sarcoma? An analysis of molecular pathways reveals epigenetic silencing of PTEN 399
D.P. Dittmer, D. Roy, S.E. Krown, B. Damania
- 141 Phase I study of JI-101, a novel oral tyrosine kinase inhibitor that selectively targets EphB4, VEGFR2, and PDGFR β 400
M. Gordon, S. Sharma, L. Miller, N. Srinivas, M. Sahu, R. Govindarajan, R. Mullangi, M. Velleca, D. Brittelli
- 142 Evaluation of pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects 401
R. Abbas-Borhan, S. Chalon, C. Leister, M. El Gaaloul, D. Sonnichsen
- 143 JX-594, a targeted multi-mechanistic oncolytic poxvirus, infects tumor vasculature and causes acute tumor vascular disruption and necrosis in advanced cancer patients 402
C. Breitbach, R. Patt, N. De Silva, K. Parato, M. Daneshmand, T. Hickman, J.C. Bell, D.H. Kirn
- 144 Phase I study on RGB-286638, a novel, multi-targeted protein kinase inhibitor, administered as a 1-hour infusion on five consecutive days every 4 weeks in patients (pts) with recurrent or refractory solid tumors 403
M. de Jonge, R. Mathijssen, W. Loos, H. Lofrerer, S. Sperka, T. Meyer, E. Wiemer, D. van der Biessen, H. Burger, J. Verweij
- 145 Phase I study of MEDI-575, a fully human monoclonal antibody targeting PDGFR-alpha in subjects with advanced solid tumors 404
R. Lechleider, C. Becerra, M. Liang, R. Narwal, L. Shi, P. Conkling, M. Galsky, R. Jotte, H. Wu, N.J. Vogelzang

- 146 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments 405
J.E. Ang, J.A. Clarkson-Jones, H. Swaisland, A.T. Brunetto, R. Lal, A.P. Farnsworth, L.R. Molife, S.B. Kaye, J. Carmichael, J.S. de Bono
- 147 Phase 2 study of XL184 in a cohort of patients (pts) with castration resistant prostate cancer (CRPC) and measurable soft tissue disease 406
D.C. Smith, A. Spira, J. De Grève, L. Hart, S. Holbrechts, C.C. Lin, M. Hussain, S. Herrick, K. Houggy, N. Vogelzang
- 148 Phase 2 study of XL184 in a cohort of ovarian cancer patients (pts) with measurable soft tissue disease 407
I. Vergote, A. Sella, C. Bedell, L. Ramondetta, G.I. Shapiro, K. Balic, E. Prokopczuk, L. Sauer, L. Tseng, R. Berger
- 149 Phase 2 study of XL184 (BMS-907351) in a cohort of patients (pts) with hepatocellular carcinoma (HCC) 408
E. Van Cutsem, W.C. Su, J. Davis, N. Haas, T.A. Samuel, C.J. Tsao, T.S. Yang, H. Brandy, G. Mann, A. Cohn
- 150 The novel, investigational Nedd8-activating enzyme inhibitor MLN4924 in patients with metastatic melanoma: a phase 1 study 409
O. Hamid, B.J. Dezube, M.D. Pickard, M.A. Shultz, S. Bhatia
- 151 Vandetanib, docetaxel and carboplatin followed by maintenance vandetanib or placebo in patients with stage IIIB, IV or recurrent non-small cell lung cancer (NSCLC): a randomized phase II study (PrE0502) by PrECOG, LLC (NCT006872970) 410
J. Aisner, J. Manola, S. Dakhil, P. Stella, J. Schiller
- 152 A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies 411
A.P. Moore, S. Thomas, C.J. Ryan, T.M. Jahan, S.G. DuBois, J.K. Chan, K.T. Thurn, A. Reinhert, A. Daud, P.N. Munster
- 153 BMS-754807, an oral dual IGF-1R/insulin receptor (IR) inhibitor: initial results from a Phase 1 dose- and schedule-finding study in combination with carboplatin/paclitaxel in subjects with solid tumors 412
Q.S. Chu, S.W. Kim, P.M. Ellis, L. Mileschkin, R.H. de Boer, J.S. Park, T. Pellas, F. Huang, F. Graf Finckenstein, A. Dhar
- 154 Phase II study evaluating the efficacy, safety and pharmacodynamic correlative study of dual anti-angiogenic inhibition using Bevacizumab (B) in combination with Sorafenib (S) in patients (pts) with advanced malignant melanoma 413
D. Mahalingam, M. Beeram, J. Rodon, K. Sankhala, A. Mita, D. Benjamin, J. Michalek, A. Tolcher, J. Wright, J. Sarantopoulos
- 155 Clinical pharmacokinetics and pharmacodynamics of CX-4945, a novel inhibitor of protein kinase CK2: Interim report from the phase 1 clinical trial 414
C.S. Padgett, J.K.C. Lim, R.F. Marschke, D.W. Northfelt, E. Andreopoulou, D.D. Von Hoff, K. Anderes, D.M. Ryckman, T.K. Chen, S.E. O'Brien
- 156 A phase I study evaluating the safety profile and pharmacokinetics of CS-1008 (Tigatuzumab), humanized monoclonal antibody targeting death receptor 5 (DR5), in Japanese patients with advanced solid tumours 415
H. Nokihara, N. Yamamoto, Y. Yamada, H. Asahina, T. Shibata, Y. Seki, Y. Tamura, K. Honda, S. Misawa, T. Tamura
- 157 The oral HDAC inhibitor SB939 shows activity in in vitro and in vivo models of acute myeloid leukemia 416
V. Diermayr, L.C. Ong, Y.K. Loh, A. Cheong, S. Hart, K.C. Goh, H.H. Hentze, H. Wang, K.E. Ethirajulu, J.M. Wood
- 158 Human biotransformation of olaparib (AZD2281) an oral poly(ADP-ribose) polymerase (PARP) inhibitor 417
J. Clarkson-Jones, C. Page, S. Sarda, H. Swaisland
- 159 Phase I, clinical, pharmacokinetic and schedule dependency study of the aurora kinase inhibitor AS703569 combined with gemcitabine in patients with solid tumors 418
E. Raymond, J. Alexandre, T. Besse-Hammer, S. Faivre, B. Longerey, N. Rejeb, A. Seithel, L. Trandafir, A. Awada

160	Pharmacokinetic (PK) assessment of bosutinib (SKI-606) administered orally to patients with advanced solid tumors in a phase 1 study <i>R. Abbas-Borhan, J. Boni, P. Hsyu</i>	419
161	Population pharmacokinetic and pharmacodynamic modelling of E7820 in patients with solid tumor <i>B. Mistry, O. Majid, C. Farrell, D. Rossignol, C. Okereke, J. Fan, Z. Hussein, A. El-Khoueiry, M. Sawyer, C. Rocha-Lima</i>	420
162	A Phase Ib study to evaluate the pan-PI3K inhibitor GDC-0941 with paclitaxel and carboplatin with and without bevacizumab in non-small cell lung cancer patients <i>J.C. Soria, C.A. Gomez-Roca, J.A. Ware, A.A. Adjei, R.K. Brachmann, H.J.M. Groen</i>	421

Nanotechnology, drug delivery, new formulations, prodrugs

Poster board	Abstract number
163 Targeting the SH2 domain of Stat3 with phosphopeptide mimetic prodrugs leads to tumor growth inhibition and down-regulation of phosphoTyr705 Stat3 and angiogenic pathways <i>J. McMurray, J. Klostergaard, E.J. Auzenne, W.S.L. Liao, Z. Lu, P.K. Mandal, R. Ramesh, M. Shanker, A.W. Scott</i>	422
164 Phase I dose escalation, safety and pharmacokinetic study of IT-101 (CRLX101), a novel nanopharmaceutical containing camptothecin, in advanced solid tumor cancer patients <i>Y. Yen, T. Synold, G.J. Weiss, T. Schluep, J. Ryan</i>	423
165 Development of novel cancer cell-selective cell-penetrating peptides for the advanced peptide-based drug delivery system <i>E. Kondo</i>	424
166 Significantly enhanced therapeutic profile of docetaxel in novel nanopharmaceutical CRLX288 <i>S. Eliasof, P.S. Ng, P. Lim Soo, J. Podobinski, R.I. Case, P. Shum, J.G. Martinez, S.R. Kabir, D. Lazarus, S. Svenson</i>	425
167 Phase I study of oral CP-4126, a gemcitabine analog, in patients with advanced solid tumours <i>F.E. Stuurman, E.E. Voest, A. Awada, J.H.M. Schellens, P.O. Witteveen, T. Bergeland, P.A. Hals, A. Hendlisz</i>	426
168 The development and evaluation of an experimental model for assessing convective fluid flow through multicell layers <i>R. Phillips, H. Makeen, N. Periasamy, P. Loadman, S. Smye, B. Sleeman, P. Jones, C. Evans, C. Twelves</i>	427
169 Targeting delivery systems mediated by a novel peptide for breast cancer therapy and imaging <i>H.C. Wu, M.S. Chen, C.Y. Chiu</i>	428
170 Design and development of nanocarrier for efficient drug delivery into the brain <i>A. Orthmann, R. Zeisig, I. Fichtner</i>	429

Natural products, new cytotoxics, clinical trials

Poster board	Abstract number
171 Dose finding of inecalcitol, a new VDR agonist, in combination with docetaxel–prednisone regimen for castrate-resistant prostate cancer (HRPC) patients (pts) <i>J. Medioni, G. Deplanque, J.M. Ferrero, T. Maurina, J.M. Rodier, E. Raymond, G. Allyon, S. Renaux, J.F. Dufour-Lamartinie, S. Oudard</i>	430
172 Triterpene extract of Ganoderma lucidum inhibits proliferation of pre-malignant human prostate cells by regulation of epithelial mesenchymal transition <i>Y.F. Lee, D.A. Guo, N. Thomas, S.A. Watson</i>	431
173 Phase Ib study of plitidepsin with bevacizumab in refractory solid tumor patients (pts) <i>C. Gomez-Roca, T. Besse-Hammer, S. Szyldergemajn, R. Bahleda, M. Diaz, A. Vandermeeren, S. Extremiera, C. Kahatt, J.C. Soria, A. Awada</i>	432
174 Anti-cancer activity of onconase, a cytotoxic amphibian ribonuclease, in combination with standard of care agents in non-small cell lung tumorgraft models <i>E.M. Bruckheimer, S.J. Strawn, M.J. Wick, F. Nieves, S. Saxena, W. Ardel, E.K. Rowinsky, D. Sidransky</i>	433
175 First-in-man phase I study of PM01183 using an accelerated titration design <i>M.J. Ratain, M.E. Elez, S. Szyldergemajn, D. Geary, S.P. Kang, T. Maraculla, A. Yovine, A. Soto-Matos, J. Tabernero</i>	434

176	Endoplasmic reticulum stress mediates immunogenic cancer cell death via the phosphoinositide 3-kinase pathway <i>Y. Yang, L.B. Zhang, L. Qiang</i>	435
177	NBRI16716A, a new antitumor compound against prostate cancer cells, produced by <i>Perisporiopsis melioloides</i> Mer-f16716 <i>M. Kawada, I. Momose, T. Someno, H. Inoue, S. Ohba, T. Masuda, D. Ikeda</i>	436
178	The synergistic antitumorigenic effects of vinblastine and total <i>Astragalus</i> saponins (AST) with reduced invasiveness of colon cancer cells <i>J.K. Ko, K.K. Auyeung, P.C. Law</i>	437
179	Imidazotetrazinone prodrugs (temozolomide analogues) with activity independent of mismatch repair and alkyltransferase <i>R.T. Wheelhouse, D. Pletsas, L. Li, E.A.E. Garelnabi, R.M. Phillips</i>	438
180	Rapid effects of Irvalec on tumor cell integrity associated with changes in the ionic membrane conductance <i>J.M. Molina-Guijarro, A. Macias, C. Garcia, V. Moneo, D. Miren, J.F. Martinez-Leal, M.P. Lillo, L. Garcia-Fernandez, C. Valenzuela, C.M. Galmarini</i>	439
181	The dietary phytochemical fisetin triggers apoptosis in breast cancer cell lines: Basis for a therapeutic modality? <i>M. Smith, C. Giacomantonio, D.W. Hoskin</i>	440

Structure–activity relationship

Poster board	Abstract number
182 The discovery of novel, highly potent inhibitors of BRAF <i>I. Niculescu-Duvaz, D. Menard, D. Niculescu-Duvaz, A. Zambon, L. Davies, N. Preece, R. Kirk, S. Whittaker, R. Marais, C. Springer</i>	441
183 Triarylpyrroles, dual inhibitors of the MDM2–p53 and MDMX–p53 protein–protein interactions <i>T. Blackburn, H. Ahmed, C.R. Coxon, B.T. Golding, R.J. Griffin, H. Newell, J. Liu, X. Lu, J. Lunec, I.R. Hardcastle</i>	442
184 Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK) <i>K.M. Clapham, T. Rennison, S. Rodriguez-Aristegui, J. Bardos, N.J. Curtin, B.T. Golding, I.R. Hardcastle, D.R. Newell, C. Cano, R.J. Griffin</i>	443
185 Novel 2,3-dihydroimidazo[1,2-c]quinazolines PI3K inhibitors: Discovery and SAR <i>W.J. Scott, M. Hentemann, B. Rowley, C. Bull, A.M. Bullion, J. Johnson, A. Redman, N. Liu, R. Jones, E. Sibley</i>	444
186 Structure-based design of C8-substituted O6-alkylguanine CDK1 and 2 inhibitors <i>B. Carbain, C. Roche, J.A. Endicott, B.T. Golding, I.R. Hardcastle, C. Cano, L. Zhen-Wang, D.R. Newell, M.E.M. Noble, R.J. Griffin</i>	445
187 Optimisation of tetrahydroisoquinoline based microtubule disruptors as anti-cancer agents <i>M.P. Leese, F. Jourdan, E. Ferrandis, S. Regis-Lydi, P.G. Kasprzyk, C. Stengel, S.P. Newman, A. Purohit, M.J. Reed, B.V.L. Potter</i>	446
188 Stereoisomerism significantly impacts on the anticancer activity of novel oxaliplatin analogues in vitro and in vivo <i>U. Jungwirth, P. Heffeter, J. Gojo, S. Abramkin, K. Meelich, W. Körner, M. Micksche, M. Galanski, B.K. Keppler, W. Berger</i>	447
189 Regulation of uridine phosphorylase-2 redox-control mechanism to improve capecitabine selectivity <i>G. Pizzorno, A. Ziemba, T. Le, S. Brotman, E. Hayes, S. Castronovo, Y. Gao, T. Roosild</i>	448

Toxicology-side effects

Poster board	Abstract number
190 Increased levels of serum creatine kinase caused by skin toxicity of molecularly targeted anticancer agents in phase 1 clinical trials <i>V. Moreno Garcia, R. Molife, J. Pedersen, M. Puglisi, M. Blanco, B. Basu, K. Shah, U. Banerji</i>	449
191 Glucocorticoids frequently induce survival and growth in tumor cells by activation of classical survival and proliferation pathways which should be avoided during anti-cancer therapy <i>I. Jeremias, S. Gündisch, E. Baader, E. Amtmann, H. Ehrhardt</i>	450

192	Cumulative drug toxicity experience of ARQ 197, a selective c-Met inhibitor, and its correlation with pharmacokinetic (PK) and pharmacogenomic (PG) parameters <i>F. Chai, R. Savage, E. Garmey, G. Abbadessa, Y. Chen, B. Schwartz</i>	451
193	Novel in vivo imaging of acute chemotherapy-induced vascular toxicity <i>I. Ben Aharon, H. Bar-Joseph, M. Tzabari, G. Tzarfaty, R. Shalgi, S.M. Stemmer</i>	452
194	Population pharmacokinetics (PK) and exposure/response relationships of the receptor tyrosine kinase inhibitor E7080 in phase I studies <i>A. Gupta, B. Koetz, W. Hanekom, J.P. O'Brien, J. Wanders, M. Jansen</i>	453
195	A clinical study to characterize the occurrence of mild-to-moderate diarrhea after administration of neratinib either once daily or twice daily for 14 days <i>R. Abbas-Borhan, B.A. Hug, C. Leister, J. Burns, D. Sonnichsen</i>	454
196	Evaluation of management of hypertension in response to the receptor tyrosine kinase inhibitor, E7080: a modeling and simulation approach <i>R.J. Keizer, A. Gupta, M.O. Karlsson, J. Wanders, M. Jansen, J.H. Beijnen, J.H.M. Schellens, A.D.R. Huitema</i>	455
197	Dolichol phosphate N-acetyl-glucosamine-1 phosphate transferase activity in dermal fibroblasts as a marker of chemotherapy skin toxicity in cancer patients <i>G. Kuznecova, I. Kuznecovs, K. Jegina, S. Kuznecovs</i>	456
198	In vitro and in vivo tools to assess the myelotoxicity of anti-cancer drugs <i>F. Fiorentini, M. Germani, F. Del Bene, M. Prosser, G. Pennella, A. Giusti</i>	457
199	Comparative pharmacokinetics and intermediary metabolism of 4-demethyl-4-cholesteryl-oxycarbonylpenclomedine (DM-CHOC-PEN) <i>L.R. Morgan, A.H. Andrews, G. Bastian, C. Papagiannis, M. Krietlow, W. Waud, R.F. Struck</i>	458
200	Validation of a cell panel for preclinical evaluation of antitumor efficacy and toxicity of anticancer agents <i>C. Haglund, A. Åleskog, P. Nygren, J. Gullbo, M. Höglund, M. Wickström, R. Larsson, E. Lindhagen</i>	459

Friday, 19 November 2010

Poster Discussion session

Room A-C

Abstract number

09:30–10:30 **Angiogenesis and tumour microenvironment**

Chair: F. Eskens (The Netherlands)

09:30	Pharmacodynamic evaluation of pCDC2 and Wee1 signature as biomarkers of target engagement for the Wee1 tyrosine kinase inhibitor MK-1775 <i>J.D. Cheng (USA)</i>	651
09:35	Atrimer as a novel class of potent trimeric therapeutics inducing cancer cell death <i>A. Kretz Rommel (USA)</i>	331
09:40	Use of functional human cancer cell line mitochondria to explore the mechanisms of ABT-737-induced mitochondrial membrane permeabilization <i>A. Borgne-Sanchez (France)</i>	581

Discussant: F. Eskens (The Netherlands)

Chair: C. Dittrich (Austria)

10:00	A Phase 1 dose escalating study of ACE-041, a novel inhibitor of ALK-1 mediated angiogenesis, in patients with advanced solid tumors <i>S. Sharma (USA)</i>	465
10:05	PI3K inhibition is necessary and sufficient to induce an anti-angiogenic response in vivo based on suppression of tumor vascular structure <i>D. Sampath (USA)</i>	466
10:10	⁸⁹ Zr-bevacizumab PET imaging in renal cell carcinoma patients: feasibility of tumor VEGF quantification <i>S.F. Oosting (The Netherlands)</i>	221

Discussant: C. Dittrich (Austria)

Plenary session 8

Room A-C

Abstract number

11:00–13:05	Angiogenesis and tumour microenvironment Chairs: C.J.A. Punt (The Netherlands) and L.M. Ellis (USA)	
12:15	Immunotherapy in 2010 – still alive? <i>C. Punt (The Netherlands)</i>	463
11:50	Micro-environmental influences on cancer stem cells <i>L. Ellis (USA)</i>	462
11:00	Antiangiogenic drug alterations of the tumor microenvironment which can impact chemotherapy efficacy <i>R. Kerbel (Canada)</i>	460
11:25	Third generation anti-angiogenic strategies: novel players, novel principles <i>P. Carmeliet (Belgium)</i>	461
12:40	Molecular imaging of therapy response <i>W. Weber (Germany)</i>	464

Poster Sessions

Angiogenesis, metastasis and inhibitors

Poster board	Abstract number
001 A Phase 1 dose escalating study of ACE-041, a novel inhibitor of ALK-1 mediated angiogenesis, in patients with advanced solid tumors <i>S. Sharma, J.C. Bendell, H. Hurwitz, C.H. Condon, B.J. Thornell, P.L. Slatcher, N.G. Borgstein, M.L. Sherman, M.S. Gordon</i>	465
002 PI3K inhibition is necessary and sufficient to induce an anti-angiogenic response in vivo based on suppression of tumor vascular structure <i>D. Sampath, T. Cao, J. Oeh, K.H. Barck, H.B. Reslan, S. Wyatt, S. Ungersma, H. Koeppen, L.S. Friedman, R.A.D. Carano</i>	466
003 Updated efficacy and safety results for a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P) and bevacizumab (B) in stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC): The FALCON trial <i>E.B. Garon, J. Neidhart, J.D. Neidhart, F. Kabbinavar, N. Gabrail, M. Ribeiro de Oliveira, S.P. Lu, J. Balkissoon</i>	467
004 Anti-tumoral and anti-metastatic activity of a tetravalent bispecific antibody (TAvi6) targeting VEGF and Angiopoietin-2 <i>W. Scheuer, M. Thomas, M. Baehner, S. Seeber, H. Kettenberger, J. Schanzer, U. Brinkmann, M. Weidner, J. Regula, C. Klein</i>	468
005 Therapy monitoring of Sorafenib effect on experimental prostate carcinomas using dynamic contrast-enhanced (DCE)-MRI with Gadobutrol and immunohistochemical analyses <i>C.C. Cyran, P.M. Paprottka, B. Schwarz, C.J. Bruns, O. Dietrich, R. Hinkel, J. Von Einem, M.F. Reiser, K. Nikolaou, B.J. Wintersperger</i>	469
006 E-cadherin plasticity in tumor-initiating stem-like cells regulates prostate cancer cell invasion <i>K. Bae, N. Parker, J. Vieweg, D.W. Siemann</i>	470
007 Inhibiting signalling by erbB receptor tyrosine kinases with AZD8931, a potent reversible small molecule inhibitor, reduces intestinal adenoma formation in the ApcMin/+ mouse model <i>D. Alferez, A. Logié, P. Seedhar, R. Poulson, T. Klinowska, R.W. Wilkinson</i>	471
008 A phase I study of IMG388, an antibody drug conjugate targeting α_v integrin, in patients with solid tumors <i>J. Bendell, K. Moore, A. Qin, D. Johnson, J. Schindler, K. Papadopoulos, A.W. Tolcher</i>	472
009 Mesenchymal stromal cells enhance the malignant potential of human colorectal cancer cells by inducing epithelial–mesenchymal transition (EMT)-related phenomena <i>V. Mele, M.G. Muraro, V. Lorber, D. Calabrese, C. Giovenzana, M. Heberer, C. Bocelli-Tyndall, L. Terracciano, G.C. Spagnoli, G. Iezzi</i>	473
010 The role of epithelial to mesenchymal transition (EMT) in the establishment of colorectal liver metastases. A potential source of prognostic biomarkers <i>A. Reece-Smith, R. Argent, D. Onion, S. Watson</i>	474
011 Protease nexin 1 cleavage by MMP-9 modulates prostate cancer cell proliferation and tumorigenesis via regulation of the hedgehog pathway <i>C. McKee, D. Xu, Y. Cao, S. Kabraji, D. Allen, R. Muschel</i>	475
012 The selective $\alpha_5\beta_1$ integrin antagonist, CLT-28643, inhibits tumors angiogenesis and growth <i>P. Caldirola, U. Bäckman, Y. Cao</i>	476
013 The high invasive activity of S-adenosylmethionine decarboxylase-transformed fibrosarcoma cells is regulated by hepatocyte growth factor–Met signaling <i>M. Yin, E. Hölttä</i>	477
014 Bcl-2 regulates HIF-1 α protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90 β <i>D. Trisciuglio, C. Gabellini, M. Desideri, E. Ziparo, D. Del Bufalo</i>	478
015 Amphiregulin contributes to tumor progression in lung adenocarcinoma <i>M. Xie, T. Nukiwa, N. Nukiwa, L. Zhang</i>	479
016 Design of improved calixarene-based anti-tumor agents <i>R.P.M. Dings, J.I. Levine, M.L. Loren, T.R. Hoye, K.H. Mayo</i>	480

017	Serum levels of placental growth factor correlate with survival in patients with neuroendocrine tumors of the pancreas <i>G. Hilfenhaus, U.F. Pape, T. Webhofer, M. Schröder, M. Welzel, G. Hess, D. Zdunek, B. Wiedenmann, K. Detjen, C. Fischer</i>	481
018	INK128, a potent and selective TORC1/2 inhibitor, demonstrates anti-tumor activity in preclinical models of renal cell carcinoma by a distinct mechanism <i>Y. Liu, K. Jessen, S. Wang, L. Kessler, L. Li, L. Darjania, M. Martin, P. Ren, P. Klein, C. Rommel</i>	482
019	Pleiotropic stromal effects of VEGFR2 antibody therapy in renal cell carcinoma models <i>I. Duignan, E. Corcoran, A. Pennello, M.J. Plym, J.D. Schwartz, H. Youssoufian, L. Witte, D. Surguladze, J.R. Tonra</i>	483
020	Angiogenesis-related gene profiles with predictive value in advanced ovarian carcinoma (AOC) <i>M. Mendiola, J. Barriuso, A. Redondo, I. Sánchez-Navarro, M. Miguel-Martín, R. Madero, A. Hernández, E. Espinosa, J. De Santiago, D. Hardisson</i>	484
021	Restoration of paracrine signalling within the tumour microenvironment increases tumour growth and activation of c-Met <i>R. Argent, R. Kumari, P. Clarke, D. Onion, D. Lobo, S. Watson, A. Grabowska, P. King, B. Hall, M. Page</i>	485
022	Phenotypic characterization of circulating tumor cells (CTCs) in triple negative breast cancer patients <i>G. Kallergi, S. Agelaki, A. Mathioudaki, D. Mavroudis, V. Georgoulas</i>	486
023	The axon guidance molecule Slit2 regulates the motility of neuroendocrine cancer cells <i>K. Detjen, A. Göhrig, G. Hilfenhaus, M. Welzel, M. Schröder, B. Wiedenmann, C. Fischer</i>	487
024	Cytoplasmic mislocalization of RUNX3 by activated Shh is correlated with the development of TGF- β resistance in gastric cancer <i>J. Kim, M. Kang, H. Kang, J. Kim, S. Oh, Y. Yoo</i>	488
025	LC06, a novel angiopoietin-2 selective human antibody with potent anti-tumoral and anti-angiogenic efficacy in different xenograft models <i>M. Thomas, W. Scheuer, M. Baehner, K. Kaluza, C. Gassner, S. Seeber, H. Reiersen, A. Kavlie, J. Regula, C. Klein</i>	489
026	MMP-9 as a stromal target in cancer <i>L. Devy, B. Fingleton, M. Pham, Q. Chang, K.J. Carter, A. Dozier, D.T. Dransfield</i>	490

Cell-cycle-interactive agents

	Poster board	Abstract number
027	NCIC CTG IND.177: Phase I study of AT7519M given as a short infusion twice weekly <i>S.J. Hotte, E.X. Chen, L. McIntosh, H.W. Hirte, S. Turner, A. Jarvi, M.S. Squires, L. Seymour</i>	491
028	GNE-900, an orally bioavailable selective CHK1 inhibitor, illustrates that optimal chemosensitization is schedule and tumor type dependent <i>S. Malek, E. Blackwood, T. O'Brien, J. Epler, I. Yen, J. Ramiscal, S. Schmidt, Y. Xiao, J. Choi, P. Jackson</i>	492
029	AS703569/R763, a pan Aurora kinase inhibitor, shows strong antitumor activity in vitro and in vivo in a panel of triple-negative breast cancer cell lines and xenografts <i>E. Marangoni, A. Clark, F. Assayag, S. Chateau-Joubert, A. Hamini, M.F. Poupon, E. Liu, A. Spooner, A. Romanelli, D. Decaudin</i>	493
030	A phase I trial of SCH900776, a selective inhibitor of checkpoint kinase CHK-1, in combination with Gemcitabine in advanced solid tumors <i>A. Daud, C. Soon, G. Springett, D. Mendelson, P. Munster, J. Goldman, J. Strosberg, G. Kato, J. Horowitz, L. Rosen</i>	494
031	Pharmacological profile of the novel pan-CDK inhibitor BAY 1000394 in tumor models of human small cell lung cancer, breast and prostate cancer as monotherapy and combination treatment <i>G. Siemeister, A. Wengner, U. Lücking, P. Lienau, W. Steinke, C. Schatz, D. Mumberg, K. Ziegelbauer</i>	495
032	A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours <i>M. Scheulen, K. Mross, H. Richly, B. Nokay, A. Frost, D. Scharr, K.H. Lee, O. Saunders, J. Hilbert, O. Fietz</i>	496

033	Combination therapy with an Aurora B kinase inhibitor AZD1152 and AraC, shows enhanced tumouricidal activity in a preclinical model of acute myeloid leukaemia (AML) <i>R.W. Wilkinson, R. Odedra, S.V. Holt, J.R. Foster, E. Anderson</i>	497
034	In vivo evaluation of TAK-960, a novel, orally bioavailable inhibitor of Polo-like kinase 1 <i>Y. Hikichi, I. Kaieda, K. Honda, H. Miyashita, K. Hikami, S. Murai, L. Zhang, J. Yang, K. Kuida</i>	498
035	Metastatic lung cancer proliferation is inhibited by Caveolin-1 silencing <i>A. Gasperi Campani, F. Pancotti, L. Roncuzzi</i>	499
036	A novel pyrazolo[4,3-d]pyrimidine inhibitor of cyclin-dependent kinases: antiproliferative and proapoptotic effects <i>R. Jorda, E. Reznickova, V. Krystof, L. Havlicek, M. Strnad</i>	500
037	4SC-207, a novel and highly potent anti-mitotic agent, active also on P-gp expressing tumor cells resistant to other chemotherapeutic drugs, induces complete tumor stasis in vivo <i>A. Ammendola, R. Doblhofer, S. Strobl, S. Hamm, M. Schmidt, P. Gimmnich, K. Pekari, A. Zimmermann, B. Hentsch</i>	501
038	Polyploidy, senescence and apoptosis: distinctive phenotypic features of cancer cells treated with BI 811283, a novel Aurora B kinase inhibitor with anti-tumor activity <i>U. Gürtler, U. Tontsch-Grunt, M. Jarvis, S.K. Zahn, G. Boehmelt, J. Quant, G.R. Adolf, F. Solca</i>	502
039	In vitro characterization of TAK-960, a novel, small molecule inhibitor of Polo-like kinase 1 <i>N. Uchiyama, T. Kawamoto, I. Kaieda, K. Honda, H. Miyashita, K. Hikami, Y. Hikichi, K. Kuida</i>	503
040	The role of interferon-gamma- and TNF-induced cell cycle arrest in insulinoma <i>S. Fischer, H. Braumüller, T. Wieder, F. Essmann, W. Kempf, M. Röcken</i>	504
041	Dual Cdc7/Cdk9 kinase inhibitor, PHA-767491, targets both quiescent and proliferating CLL cells <i>A. Santocanale, A. Natoni, L. Murillo, M. Catherwood, A. Montagnoli, A. Samali, M. O'Dwyer</i>	505

Radiation interactive agents

Poster board

Abstract number

042	Darinaparsin (ZIO-101) is a novel cytotoxic and radiosensitizing agent for prostate cancer <i>S. Knox, J. Tian, D. Peehl</i>	506
043	Sensitization of hypoxic cells to ionising radiation by a hypoxia activated inhibitor of DNA dependent protein kinase <i>K.E. Lindquist, J.D. Cran, K. Kordic, A.H. Kyle, A.I. Minchinton</i>	507
044	Radiation-induced c-Met expression sensitizes lung cancer cells to c-Met antagonists <i>J. Welsh, Y. Zhan, A. Likhacheva, R. Komaki</i>	508
045	Bortezomib enhances radiosensitivity in solid tumor cells through down-regulation of CIP2A <i>C.Y. Huang, K.F. Chen, Y.C. Lin, A.L. Cheng</i>	509
046	5-azacitidine restores and amplifies the response to bicalutamide and radiotherapy on preclinical models of androgen receptor expressing or deficient prostate tumors <i>G. Giovanni Luca, C. Festuccia, F. Marampon, P. Bonfili, M. Di Staso, S. Di Sante, R.G. Pestell, V. Tombolini</i>	510
047	MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by down regulating growth and DNA repair signals <i>F. Marampon, G.L. Gravina, P. Bonfili, M. Di Staso, L. Polidoro, C. Festuccia, R.G. Pestell, B.M. Zani, V. Tombolini</i>	511

DNA repair and inhibitors

Poster board

Abstract number

048	NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion <i>K. Gelmon, S. Dent, K. Chi, D. Jonker, N. Wainman, R. Simpson, K. Capier, E. Chen, M.S. Squires, L. Seymour</i>	512
049	Chemo-sensitization using cancer targeted Spermidine–CoA based compound <i>K. Bandyopadhyay, J. Banères, A. Martin, C. Blonski, J. Parello, R. Gjerset</i>	513
050	Sensitisation of paediatric solid tumours to DNA-damaging chemotherapy by inhibition of DNA-dependent protein kinase (PRKDC) <i>B. Vormoor, K.E. Foy, N. Curtin, S.C. Clifford</i>	514

051	Therapeutic advantage of chemotherapy drugs in combination with PARP inhibitor PF-01367338 (AG-014699) in human ovarian cancer cells <i>M. Ihnen, K. Manivong, M. Chalukya, J. Dering, T. Kolarova, G. Los, J. Christensen, R.S. Finn, D.S. Slamon, G.E. Konecny</i>	515
052	A phase 1 dose-escalation study to examine the safety and tolerability of LY2603618 administered 1 day after pemetrexed 500 mg/m ² every 21 days in patients with cancer <i>G. Weiss, R. Donehower, E. Westin, A. Bence, S. Hynes, K. Hurt</i>	516
053	Combining pemetrexed with temozolomide and TRC102 (methoxyamine) causes synergistic cytotoxicity in melanoma cells <i>L. Liu, A. Bulgar, B. Adams, C. Theuer, B. Leigh, S. Gerson</i>	517
054	CX-4945, an inhibitor of protein kinase CK2, disrupts DNA damage repair, potentiates apoptosis and enhances antitumor activity of gemcitabine in a model of ovarian cancer <i>K. Anderes, J. Bliesath, C. Ho, M. Omori, N. Huser, A. Siddiqui-Jain, N. Streiner, C. Proffitt, S. O'Brien, D. Drygin</i>	518
055	Are the methylation of MGMT (O6-methylguanine-DNA methyltransferase) and the DNA mismatch repair (MMR) mechanism frequently involved in pediatric cancers? <i>A. Nguyen, M. Legrain, A. Newville, E. Pencreach, E. Guerin, P. Lutz, M.P. Gaub, D. Guenot, N. Entz-Werle</i>	519
056	NMS-P118, a Parp-1 selective inhibitor with efficacy in DNA repair deficient tumor models <i>A. Montagnoli, S. Rainoldi, F. Sola, H. Poster, R. Lupi, E. Pesenti, D. Donati, J. Moll, D. Pezzetta, G. Papeo</i>	520
057	EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment <i>G. Liccardi, J.A. Hartley, D. Hochhauser</i>	521
058	The marine-derived product PM01183 shows activity toward platinum-resistant cells and attenuates nucleotide excision repair <i>D.G. Soares, C.J. Rocca, M. Machado, V. Poindessous, D. Ouaret, A. Sarasin, C. Galmarini, J.A.P. Henriques, A.E. Escargueil, A.K. Larsen</i>	522
059	The XRCC1 Arg280His polymorphism is associated with high-grade radiation-induced late toxicity in prostate cancer patients <i>T. Langsenlehner, W. Renner, G. Hofmann, E.M. Thurner, K.S. Kapp, U. Langsenlehner</i>	523
060	Potent DNA alkylating agents against human prostate cancer in xenograft model <i>T. Su, R. Kakadiya, Y.R. Chen, H. Dong, A. Kumar, P.W. Hsiao, T.C. Lee, T.C. Chou</i>	524

Gene therapy and antisense approaches

Poster board		Abstract number
061	Design and synthesis of N10-protected pyrrolobenzodiazepine (PBD) prodrugs for use in nitroreductase-mediated GDEPT therapies <i>C.L. von Bulow, K. Stevenson, J. Plumb, P.W. Howard, W.N. Keith, D.E. Thurston</i>	525
062	A potent PBD-heterocyclic polyamide conjugate targeting an ICB2 transcription factor binding site <i>F. Brucoli, R.M. Hawkins, G. Wells, T.C. Jenkins, T. Ellis, M. Kotecha, D. Hochhauser, J.A. Hartley, P.W. Howard, D.E. Thurston</i>	526
063	siRNA targeting of thymidylate synthase and thymidine kinase for anti-cancer therapy <i>C. Di Cresce, P.J. Ferguson, R. Figueredo, M.D. Vincent, J. Koropatnick</i>	527
064	Observation of the reversibility of formation of a pyrrolobenzodiazepine (PBD) covalent DNA adduct using HPLC/MS and CD spectroscopy <i>K.M. Rahman, C.H. James, D.E. Thurston</i>	528
065	Endocytosis and intracellular trafficking of cholesterol based cationic liposome for gene delivery <i>K. Doh, Y. Bae</i>	529
066	Activity of the TGF-beta2 specific antisense oligodeoxynucleotide trabedersen in an orthotopic xenograft mouse model of metastatic pancreatic cancer <i>F. Jaschinski, S.A. Lang, C. Moser, H.J. Schlitt, A. Schneider, K.H. Schlingensiepen</i>	530
067	Host cell specific responses to a novel rVSV oncolytic vector rNCP12.1 <i>E. Dillard, C. Duntsch, L.M. Pfeiffer, M.A. Whitt</i>	531
068	Down-regulation of MET via DNA triplex-forming oligodeoxyribonucleotides targeting the promoter of c-Met gene results in growth inhibition and apoptosis in liver cancer <i>G. Singhal, D. Stern, S. Datta Gupta, A. Ahuja, U. Sharma, N.R. Jagannathan, M.R. Rajeswari</i>	532

069	Evaluation of the role of mir-34b in modulation of radioresistance in non-small-cell lung cancer <i>J. Silva, S.S. Neves, A.C. Gonçalves, M. Abrantes, L. Mesquita, F. Botelho, A.B. Sarmento Ribeiro, H.C. Silva</i>	533
070	Fra-1 is an independent prognostic factor in esophageal squamous cell carcinoma and related to cell proliferation, migration and invasion in vitro <i>H. Matsubara, A. Usui, Y. Akutsu, I. Hoshino, K. Murakami, M. Kano</i>	534
071	miR-205-mediated reversal of epithelial–mesenchymal transition modifies the drug sensitivity profile of prostate cancer cells <i>M. Pennati, P. Gandellini, V. Profumo, N.I. Orłotti, M.G. Daidone, M. Folini, N. Zaffaroni</i>	535
072	Newcastle disease virus Iraqi local isolate as a therapy for murine mammary adenocarcinoma: In vitro and in vivo study <i>A. Al-Shammari, N. Yaseen, M. Alwan</i>	536

Genetics and epigenetics

Poster board

Abstract number

073	Potent in vitro and in vivo anti-tumor activity of ITF2357 by modulation of c-myc related miRNA signature in human Burkitt's lymphoma <i>R. Zappasodi, M.V. Iorio, A. Cavanè, M. Magni, G. Ruggiero, C. Carlo-Stella, C.M. Croce, A.M. Gianni, M. Di Nicola</i>	537
074	Id1 enhances RING1b E3 ubiquitin ligase activity through the Mel-18/Bmi-1 polycomb group complex <i>J. Lee, T. Qian, J. Park, H. Kim, G. Kong</i>	538
075	Hydroxamate-tethered short chain fatty acid designer cancer prevention molecule <i>U. Asad, C. Chen</i>	539
076	Clinical phase II development of resminostat, a novel HDAC inhibitor <i>R. Jankowsky, A. Mais, S.W. Henning, B. Hauns, B. Hentsch</i>	540
077	ERBB3 promoter polymorphisms and mRNA expression associated with lung cancer risk in Korean lung cancer patients <i>J. Sung, L. Jin, K.H. Park, S.T. Kim, H.N. Jung, J.S. Ryu, J.H. Seo, S.W. Shin, J.S. Kim, Y.H. Kim</i>	541
078	Centralised analysis of phase I ECG dataset of resminostat, a new oral histone deacetylase inhibitor (HDACi) <i>B. Hauns, A. Mais, R. Jankowsky, B. Hentsch, W. Haverkamp</i>	542
079	Human transcription factors regulated by SET protein <i>L. Almeida, A.M. Leopoldino</i>	543
080	DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy in breast cancer <i>J. Martinez-Galan, J.R. Delgado, R. Del Moral Ávila, B. Torres Torres, M.I. Nuñez, J. Valdivia, R. Luque, J. Peñalver, S. Ríos-Arrabal, M. Ruiz De Almodovar</i>	544
081	Expression of methylthioadenosine phosphorylase (MTAP) in malignant pleural mesothelioma (MPM) and its implication for pemetrexed-based chemotherapy <i>A. Abdul Razak, J. Nutt, K. O'Toole, F. Black, M. Cole, R. Plummer, J. Lunec, H. Calvert</i>	545
082	Promoter methylation of the RGC32 gene in non-small cell lung cancer and its clinical implications <i>D.S. Kim, S.M. Lee, Y.W. Jung, J.Y. Park</i>	546
083	Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide <i>S. Coral, L. Sigalotti, G. Parisi, F. Colizzi, E. Fratta, H.J.M. Nicolay, P. Taverna, M. Maio</i>	547
084	Positive inter-regulation between beta-catenin and endothelin signaling in ovarian cancer cells: epigenetic regulation of ET-1 gene expression <i>L. Rosanò, R. Cianfrocca, F. Spinella, V. Di Castro, P.G. Natali, A. Bagnato</i>	548
085	Unified carcinogenesis theory <i>V. Halytskiy</i>	549

- 086 Airway-specific administration of the demethylating agent azacytidine effectively reexpresses tumor suppressor genes and inhibits lung cancer in mice 550
Y. Zou, X. Qiu, A. Saxena, R. Perez-Soler

Pharmacogenetics

Poster board

Abstract number

- 087 Functional characteristics of human epidermal growth factor receptor (EGFR) polymorphisms 551
A.A. Adjei, H. Huang, G.K. Dy, O.E. Salavaggione, C. Endo, C. Yu
- 088 CYP3A5*3 (rs776746) is associated with docetaxel-specific toxicities during adjuvant breast cancer chemotherapy 552
S. Damaraju, S. Ghosh, J. Tuszyński, R. Greiner, R. Lai, C. Cass
- 089 The influence of CYP2D6 and CYP3A5 pharmacogenetics on pharmacokinetics of tamoxifen and its metabolites in Asian breast cancer patients 553
B. Chowbay, J.S.L. Lim, O. Singh, R.C.H. Ng, N.S. Wong, E.J.D. Lee
- 090 Histone deacetylase inhibitors mediate pharmacological rescue and increase membrane expression of ABCG2 harboring the Q141K single nucleotide polymorphism 554
S.E. Bates, A. Tamaki, Y. Ward, C. Ierano, R.W. Robey, R. Hegde, K.K.W. To

RNA and DNA based technologies

Poster board

Abstract number

- 091 Advancement of ALN-VSP, an experimental RNAi therapeutic for solid tumors 555
I. Toudjarska, T. Buck, J. Brodsky, A. Akinc, T. Racie, J. Gollob, D.W.Y. Sah, D. Bumcrot
- 092 Therapeutic siRNA delivery against PKN3 improves the antineoplastic efficacy of gemcitabine in an orthotopic pancreatic cancer model 556
O. Stoeltzing, H. Nagata, K. Staufer, A. Mori, M. Aleku, J. Kaufmann, C. Moser, T.Y. Tsui, B. Nashan
- 093 Generation of microRNA-sensitive VSV vectors to reduce neurotoxic side effects 557
S. Apfel, J. Altomonte, O. Ebert
- 094 Systematic functional analysis of microRNAs by transfection of 1129 miRNAs into prostate cancer cells 558
R. Bjerkvig, S.K. Leivonen, P. Östling, A. Aakula, P. Kohonen, R. Mäkelä, Z. Hagman, H. Edgren, Y. Ceder, M. Perälä, O. Kallioniemi
- 095 Novel approaches to enable molecular analysis of clinical samples with limited amount of tissue 559
R. Raja, C. Wong, L. Fu, R. Patel, R. Desai, L. Amler
- 096 In vivo pharmaceutical targets screening using lentiviral inducible-knockdown shRNA system 560
Y. Yin, J. Kumari, S. Watson, A. Grabowska, B. Hall, M. Page, P. King
- 097 miR-221 as potential therapeutic target for childhood hepatoblastoma 561
H.V. Hunt, R. Sandhu, W.B. Coleman
- 098 Screening and development of novel anti-proliferative oligonucleotides with 256 guanosine and thymidine octamer 562
K. Doh, S. Lee
- 099 Prognostic value of “70-gene prognosis-signature” assay in early breast cancer 563
I. Martínez-Ferez, R. García-Estépa
- 100 Efficacy of a molecular method for detection of lymph node metastases in early breast cancer 564
R. García-Estépa, I.M. Martínez-Férez

Bioinformatics

Poster board

Abstract number

- 101 The Virtual Tumour, a predictive simulation platform to optimize anti-cancer drug scheduling and combination 565
E. Fernandez, D. Orrell, C. Snell, C. Chassagnole
- 102 Frequent overexpression of Hbo1 in non-small cell lung carcinoma and its potential oncogenic role 566
J. Park, J.Y. Lee, S.M. Chun, H.S. Seol, J. Choi, J.H. Lee, J.J. Hwang, C.S. Kim, S.J. Jang, C.M. Choi
- 103 A rationale for anti-angiogenic therapy in head and neck cancer 567
M. Kupferman, K. Hale, B. Aldred, E. El-Naggar, G. Mills, J. Myers

- 104 A permutation-based confidence interval for treatment effect in the identified subset of sensitive patients in biomarker-adaptive threshold design 568
K. Yoshimura
- 105 Whole-genome sequencing and analysis of an ovarian cancer patient 569
S. Bentink, R. Sultana, R. Rubio, U. Matulonis, J. Quackenbush

Anthracyclines, antimetabolites, antimicrotubules, topoisomerase inhibitor

Poster board

Abstract number

- 106 Phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an IV infusion every 3 weeks to patients with advanced solid tumors 570
R.J. Fram, L.E. Garbo, G.J. Weiss, D. Shkolny, A.V. Yurkovetskiy, C. Bethune, R.K. Ramanathan, M.J. Edelman, E.A. Sausville
- 107 TLC388, a novel topoisomerase-1 inhibitor with anti-hypoxia inducible factor-1 alpha activity: a phase I and pharmacokinetic study in patients with advanced solid malignancies 571
C. Lin, S.A. Ghamande, D.C. Cho, M.H. Silverman, K. Fong, M. Kuo, W. Mach, Y. Tseng, S.C. Hsu, S. Goel
- 108 Berubicin, a topoisomerase II poison with high CNS uptake, inhibits cell growth and induces apoptosis in diffuse large B-cell lymphomas 572
W. Priebe, M. Wang, L. Sun, I. Fokt, H. Bao, L. Zhang, A. Jayakumar
- 109 Eribulin and cytochrome P450 effectors: *in vitro* studies and population pharmacokinetic–pharmacodynamic analysis 573
L. Reyderman, A. Gupta, R.D. Pelletier, Y.N. Wong
- 110 Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole (KET) 574
L. Deviese, J. Wanders, A. Jenner, G. Edwards, L. Reyderman, W. Copalu, F. Peng, S. Marchetti, J.H.M. Beijnen, J.H.M. Schellens
- 111 ALB 109564(a), a novel tubulin inhibitor: phase 1 trial in patients with solid tumours 575
M.S. Clancy, J.M. Cleary, S. Mani, E. Choy, M.A. Wolf, M.H. Silverman, S.C. Gad, L.C. Cuasay, B.J. Dezube, G.I. Shapiro
- 112 *In vivo* pharmacokinetics of [11C]docetaxel in lung cancer patients 576
A.A. van der Veldt, M. Lubberink, E.F. Comans, H.N. Greuter, A. van Lingem, S.N. Rizvi, A.D. Windhorst, E.F. Smit, N.H. Hendrikse, A.A. Lammertsma
- 113 Berubicin, a novel mechanistically altered anthracycline potently inhibits cell growth and induces apoptosis in mantle cell lymphoma 577
M. Wang, L. Sun, I. Fokt, H. Bao, L. Zhang, A. Jayakumar, W. Priebe

Apoptosis, necrosis, autophagy

Poster board

Abstract number

- 114 Induction of acute apoptosis by cisplatin is not associated with damage to nuclear DNA and is likely to be an “off-target effect” 578
S. Linder, M. Olofsson, W. Fayad, M.C. Shoshan
- 115 Tumor necrosis factor and CCR5 gene associations with cancer risk 579
R. Gade Andavolu, S. Shu, M. Andavolu, S. Rubakovic, J. MacMurray
- 116 Reolysin induces endoplasmic reticular stress in multiple myeloma and enhances the activity of bortezomib 580
K.R. Kelly, C.M. Espitia, E.C. Medina, D. Mahalingam, B.O. Oyajobi, M. Coffey, F.J. Giles, J.S. Carew, S.T. Nawrocki
- 117 Use of functional human cancer cell line mitochondria to explore the mechanisms of ABT-737-induced mitochondrial membrane permeabilization 581
N. Buron, M. Porceddu, P. Rustin, E. Jacotot, A. Borgne-Sanchez
- 118 Disruption of autophagic and autolysosomal signaling pathways leads to synergistic augmentation of erlotinib-induced apoptosis in wild type EGFR human non-small cell lung cancer cell lines 582
Y. Ling, R. Perez-Soler
- 119 PI3-kinase inhibition enhances ABT-737 induced apoptosis in colorectal cancer cell lines 583
C. Morrow, O. Denny, M. Mehibel, C. Dive
- 120 c-FLIP, a critical target for histone deacetylase inhibitors in mesothelioma 584
J. Hurwitz, K. McLaughlin, E. Kerr, D. Fennell, D. Longley

121	NOXA as mediator for drug-induced apoptosis – molecular studies in patient-derived ALL cells	585
	<i>I. Jeremias, I. Höfig, N. Terziyska, H. Ehrhardt</i>	
122	Lucanthone: A novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis	586
	<i>J.S. Carew, C.M. Espitia, J.A. Esquivel II, D. Mahalingam, K.R. Kelly, G. Reddy, F.J. Giles, S.T. Nawrocki</i>	
123	Down-regulation of FLT3 kinase phosphorylation and survivin expression contributes to the activity of imidazoacridinone C-1311 against leukemia cells with FLT3 ITD mutation	587
	<i>A. Skwarska, E. Augustin, S. Sobiesiak, J. Koprowska, J. Konopa</i>	
124	Trans-membrane-p53 peptide therapy for malignant glioma	588
	<i>S. Yamada, H. Kanno</i>	
125	HDAC inhibitors induce FLIP down-regulation and caspase 8 dependent apoptosis in colorectal cancer cells	589
	<i>E. Kerr, K. McLaughlin, J. Riley, P. Johnston, D. Longley</i>	
126	Transcription factor, Id4, induced cellular reprogramming of cancer cells using an advanced prostate cancer cell model	590
	<i>J.P. Carey, J.C. Chaudhary, A.J. Asirvatham, A. Evans</i>	
127	Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated down-regulation of c-FLIP and Mcl-1 proteins	591
	<i>T.J. Lee, S.J. Lee, H.J. Noh, E.G. Sung, I.H. Song, J.Y. Kim</i>	
128	Characterisation of novel, small molecule antagonists of XIAP, cIAP1 and cIAP2 generated by fragment based drug discovery (FBDD)	592
	<i>G. Ward, G. Chessari, A. Woolford, P. Williams, K. Hearn, C. Richardson, J. Coyle, I. Buck, J. Day, E. Tamanini</i>	
129	Notch-1 fragment peptide induces autophagy and caspase-independent cell death in leukemic cell lines	593
	<i>A. Kuniyasu, M. Kurogi, S. Takahashi, S. Nishimura, H. Nakayama</i>	

Biomarkers

Poster board	Abstract number
130	In vivo detection of mammary tumor and its lung metastases in the 4T1 metastasis mouse model by PET imaging using [F-18]-D-FMT (BAY 869596)
	<i>S. Zitzmann-Kolbe, A. Strube, A.L. Frisk, H. Tsukada, V. Gekeler, K. Graham, D. Berndorff</i>
131	Preclinical activity and the role of biomarkers of sensitivity to the selective phosphatidylinositol 3'kinase inhibitor GDC-0941 in breast cancer
	<i>M. Lackner, C. O'Brien, J. Fridlyand, A. Pandita, S. Boyd, E. Punnoose, H. Koeppen, L. Friedman, L. Amler, G. Hampton</i>
132	Design and validation of pharmacodynamic assays to measure the activity of the HSP90 inhibitor, AT13387 in surrogate tissue and tumor in a phase I study
	<i>J. Lyons, M. Squires, V. Lock, B. Graham, T. Smyth, E. Ong, D. Mahadevan, E. Kwak, G. Shapiro</i>
133	Merkel cell polyomavirus (MCPyV)-negative Merkel cell carcinomas harbor frequent TP53 mutations, express p53, and are associated with unfavorable prognosis
	<i>H. Sihto, H. Kukko, V. Koljonen, R. Sankila, T. Böhling, H. Joensuu</i>
134	Association of Merkel cell polyomavirus infection with p53, KIT, PDGFR-alpha, stem cell factor and survival in Merkel cell carcinoma
	<i>M. Waltari, H. Sihto, H. Kukko, V. Koljonen, R. Sankila, T. Böhling, H. Joensuu</i>
135	Antiangiogenic effects of linifanib (ABT-869) in xenograft models and patients with solid tumors
	<i>F. Jiang, Y.P. Luo, P. Tapang, B.C. Goh, C.I. Wong, R. Soo, D. Albert, M. McKee, J.L. Ricker, E. McKeegan</i>
136	Preclinical pharmacokinetics-pharmacodynamics (PK-PD) modeling of TAK-733, an investigational MEK inhibitor
	<i>K. Le, A. Chakravarty, R. Walker, E. Izmailova, P. Vincent, S. O'Connell, S. Prakash</i>
137	Comparative tissue distribution of the HDAC inhibitor JNJ-26481585
	<i>H. Bohets, K. Van Uytsel, M. De Meulder, P. King, I. Hickson, A. Forslund, P. Palmer, S. McClue</i>
138	Identification of HSP105 as a novel non-Hodgkin lymphoma restricted antigen
	<i>S.M. Pupa, R. Zappasodi, G.C. Ghedini, L. Castagnoli, P. Aiello, F. Miccichè, A.D. Cabras, I. Bongarzone, A.M. Gianni</i>

- 139 Baseline circulating tumor cell (CTC) counts enhance the performance of the Royal Marsden Hospital (RMH) Prognostic Score and improve patient selection for phase 1 clinical trials
S. Sandhu, C. Massard, D. Papadatospastos, T. Yap, D. Olmos, R. Baird, J.S. De-bono 603
- 140 Farnesoid X receptor overexpression predicts breast cancer bone metastases through a Runx2-dependent mechanism
F. Journe, V. Durbecq, H. Boufker, D. Larsimont, G. Laurent, J.J. Body, A. Awada, G. Ghanem 604
- 141 Quantitative analyses of the impact of Akt inhibitor GDC-0068 on cell signaling and implications for clinical pharmacodynamic assessments
Y. Yan, V. Serra, D. Sampath, L. Prudkin, M. Scaltriti, B. Liederer, S. Murli, K. Lin, V. Ramakrishnan, J. Baselga 605
- 142 Integrated analysis of genome-wide copy number and expression changes reveals novel genes in oesophageal adenocarcinoma
X.Y. Goh, J.R.E. Rees, A.L. Paterson, S.F. Chin, M. O'Donovan, D. Alderson, B. YIstra, C. Caldas, R.C. Fitzgerald 606
- 143 Novel circulating biomarker of MET addiction and susceptibility to MET inhibitors
N. Ise, K. Omi, D. Nambara, K. Goishi 607
- 144 Tivozanib biomarker identifies tumor infiltrating myeloid cells contributing to tivozanib resistance in both preclinical models and human renal cell carcinoma
J. Lin, X. Sun, B. Feng, F. Jiang, G. Li, M.I. Chiu, B. Esteves, M. Al-Adhami, P. Bhargava, M.O. Robinson 608
- 145 Integrative analysis of DNA methylation and gene expression identifies a DNA methylation signature associated with erlotinib resistance in EGFR wild type non-small cell lung cancer cells
J. Wang, S. Lin, J. Yordy, L. Byers, L. Diao, J. Weinstein, K. Coombes, J. Minna, J. Heymach 609
- 146 Perioperative cancer cell dissemination is not associated with worse prognosis in pancreatic cancer
G. Sergeant, T. Roskams, J. Van Pelt, F. Houtmeyers, R. Aerts, B. Topal 610
- 147 Bcl-2 family protein expression in navitoclax-treated patients (pts) with lymphoid malignancies
B. Chyla, M. Smith, S. Tahir, W. Wilson, O. O'Connor, M. Czuczman, J. Gerecitano, S. Enschede, A. Krivoschik, E. McKeegan 611
- 148 A single FISH procedure for the detection of tumor cells: Bladder cancer as model
A. Rivas, E. Landerer, V. Burzio, S. Gatica, C. López, L.O. Burzio, J. Villegas 612
- 149 Development of monoclonal antibodies recognizing the active conformation of epidermal growth factor receptor and application for activation-specific measurement in ELISA
K. Omi, N. Ise, K. Goishi 613
- 150 The proteomic classifier VeriStrat® identifies advanced non small cell lung cancer (NSCLC) patients gaining clinical benefit from treatment with first line sorafenib and erlotinib
E. Smit, H. Roder, J. Grigorieva, J. Roder, J. Lind, A. Dingemans, H. Groen 614
- 151 The potential to personalize targeted therapy shown by in vitro kinase activity profiling in pancreatic xenograft models
S. Rangarajan, N.P. Giepmans, J. van der Hoeven 615
- 152 Imaging heterogeneity of hypoxia: spatial and temporal
K.A. Krohn, T.L. Richards 616
- 153 HER2 cytoplasmic staining as an independent risk factor for death in penile cancer
A.M.T. Silva, R.M. Rocha, I.W. Cunha, A. Cubilla, G.C. Guimarães, A. Lopes, F.A. Soares 617
- 154 Biological correlation of the expression EGFR pathway in renal cell carcinoma with Hif1-a, VEGF, VEGFR-2(Flk-1), TGF-a, VHL in tumor tissue sample levels
M. Vanessa, G. Aparicio Gallego, I. Santamarina Caínzos, M. Quindós Varela, D. Dopico Vázquez, R. García Campelo, G. Alonso-Jaudenes Curbera, L. Valbuena Rubira, E. Grande Pulido, L.M. Antón Aparicio 618
- 155 Tissue array study in renal cell carcinoma: Hif1-a, CAIX and VEGF correlation
M. Vanessa, G. Aparicio Gallego, I. Santamarina Caínzos, M. Quindós Varela, D. Dopico Vázquez, R. García Campelo, M. Valladares-Ayerbes, L. Valbuena Rubira, E. Grande Pulido, L.M. Alonso-Jaudenes Curbera 619
- 156 Discordant expression patterns of four different CD133 antibody clones in glioblastomas – possible implications for CD133 as a new therapeutic target
S.K. Hermansen, K.G. Christensen, S.S. Jensen, B.W. Kristensen 620
- 157 The three-dimensional FISH with IHC can work on circulating tumor cells
Y. Mishima, Y. Terui, S. Matsusaka, Y. Mishima, K. Hatake 621

158	Detection of genetic alterations in patients with hepatocellular carcinoma (HCC) in Coimbatore population <i>S. Mohana Devi, B. Vellingiri, A.R.U.N. Meyyalagan, K. Alagamuthu, M. Pappusamy, S. Keshavarao</i>	622
159	FDG PET/CT as an imaging biomarker for patients with metastatic renal cell carcinoma <i>N. Nakaigawa, M. Yao, R. Minamimoto, K. Namura, K. Makiyama, D. Ueno, A. Sakata, J. Kasuga, T. Inoue, Y. Kubota</i>	623
160	Establishment of a large panel of “early” colon carcinoma xenografts as a preclinical tool for identification of predictive biomarkers <i>M. Becker, B. Hinzmann, I. Klamann, H.P. Adams, A. Rosenthal, J. Hoffmann, I. Fichtner</i>	624
161	Optimization of microRNAs detection in urine samples of patients with bladder and prostate cancers <i>N. Ghorbanmehr, M. Tavallaei, B. Einollahi, M. Rafiee, S.J. Mowla</i>	625
162	Molecular characterization of circulating tumor cells using a highly sensitive method of enrichment based on the CellSearch CTC profile kit <i>V. Melnikova, Y. Zhang, M. Pace, M. Garza, S. Sukumaran, S. Zhao, J. Woo, D. Davis</i>	626
163	PI3K- and ERK-pathway biomarker comparison by IHC, IF/AQUA™ and RPPA upon AKT inhibition <i>V. Serra, L. Prudkin, C. Aura, J. Jimenez, Y. Yan, D. Sampath, S. Murli, V. Ramakrishnan, M. Scaltriti, J. Baselga</i>	627
164	Stem cell marker expression profile in colon cancer xenografts and their corresponding cell lines <i>M. Schneider, A. Maier, G. Kelter, A. Korrat, H.H. Fiebig, J.B. Schüller</i>	628
165	Genetic polymorphisms of transforming growth factor-beta1 and estrogen metabolizing enzyme in estrogen receptor-positive and -negative infiltrating ductal breast carcinoma <i>N. Babyskhina, E. Malinovskaya, A. Ivanova, N. Cherdyntseva, E. Slonimskaya, L. Gulyaeva</i>	629
166	Microarray based expression profiling of BRCA1 mutated breast tumours using a breast cancer specific array to identify a profile of BRCA1-deficiency <i>E. Lamers, G.W. Irwin, F.A. McDyer, J.M. Mulligan, F.J. Couch, R.D. Kennedy, D.P. Harkin, J.E. Quinn</i>	630
167	Mislocalization of the apoptosome protein Apaf-1 is a strong marker of drug resistance in B cell lymphomas <i>S. Pervaiz, J.L. Hirpara, T. Loh, B.C. Goh</i>	631
168	Expression of a+β+ splice variant of human telomerase reverse transcriptase (hTERT) in cytokeratin 19 (CK-19) positive circulating tumor cells (CTCs) of breast cancer patients <i>K. Parisi, A. Strati, N. Malamos, V. Georgoulas, E.S. Lianidou</i>	632
169	MicroRNA-21 expression levels are accompanied by respective alterations in PDCD4 protein levels in non-small cell lung cancer <i>I. Sourvinou, A. Markou, L. Kaklamanis, E. Tsaroucha, I. Ozaki, S. Matsushashi, E. Lianidou</i>	633
170	Patient-derived breast cancer xenografts: Molecular characteristics and growth properties <i>T. Giesemann, R. Krumbach, J. Schueler, V. Vuaroqueaux, M. Hofmann, N. Liu, A. Haegebarth, T. Beckers</i>	634
171	Novel mechanisms of taxane and platinum resistance in Oesophagogastric Cancer Cells <i>K.M. Matula, E. Collie-Duguid, R.D. Petty</i>	635
172	CD9 decreases adhesion and improves chemotactic response of B acute lymphoblastic cells: role in pathogenesis of TEL/AML1 leukemia? <i>A. Vallée, E. Dondi, J. Bonneau, A.G. Rio, N. Varin-Blank, M.D. Galibert, V. Gandemer</i>	636
173	Prediction of the human pharmacokinetics (PK) and pharmacodynamics (PD) of MLN9708, an investigational proteasome inhibitor <i>S.J. Blakemore, A. Bulychiev, A. Berger, S. Yu, M. Paton, K. Cardoza, W. Riordan, D. Berg, A. Stathis, L. Yu</i>	637
174	Novel proteins highly expressed in tumors identified by a high throughput immunoproteomic approach <i>P. Pileri, A. Pierleoni, S. Campagnoli, A. Grandi, M. Parri, R. Nogarotto, D. Cattaneo, G. Viale, P. Sarmientos, R. Grifantini</i>	638
175	Soluble Axl (sAxl) from serum defines a subpopulation of patients with breast, colon, lung, and pancreatic cancers <i>S.L. Warner, M.L. Wade, L.T. Call, H. Vankayalapati, M.A. Firpo, S.J. Mulvihill, D.J. Bearss, S. Sharma</i>	639

176	Looking for a stemness signature in prostate cancer <i>C. Le Magnen, L. Bubendorf, C. Ruiz, A. Bachmann, S. Wyler, M. Heberer, G.C. Spagnoli, C. Mengus</i>	640
177	Level of c-kit expression on pre therapeutic mediastinal lymph node biopsy does not predict its level of expression on post chemotherapy lung tumor <i>P. Mordant, O. Mercier, J. Calderaro, A. Couvelard, D. Fabre, S. Mussot, J.C. Soria, E. Deutsch, P.H. Dartevielle, E. Fadel</i>	641
178	Organic anion transporting polypeptides contribute to prostate cancer progression <i>H.M. Pressler, T.M. Sissung, D.K. Price, W.D. Figg</i>	642
179	Phosphorylated histone H3 and S6 proteins as biomarkers for targeted anti-cancer drug action measured using a combined IHC/Western method in skin biopsies <i>R. Graeser, M. Birkle, C. Obododzie-Schäfer, N. Esser, U. Fiedler, C. Schaechtele</i>	643
180	Signaling pathways contributing to head and neck carcinoma radioresistance <i>I. Skvortsova, S. Skvortsov, B. Schiestl, P. Eichberger, P. Lukas</i>	644
181	External quality control for companion molecular diagnostics using cell lines <i>I. Cree, S.J. Glaysher, P. Johnson, L. Bolton</i>	645
182	Identification of biomarkers associated with tumor progression using laser microdissected tissues from colon adenoma and cancer <i>F.T. Unger, M. Meyer, M. Spörl, A. Harasym, J. Spangenberg, H. Juhl, K.A. David</i>	646
183	Detection of miR-302, an ES-specific microRNA, in cancer cell lines and tissues <i>H. Khayatzaadeh, M.R. Rafiee, A. Malekzadeh Shafaroudi, M. Malakootian, S.J. Mowla</i>	647
184	Ex vivo assay to monitor response to chemotherapeutic agents in plucked human hairs <i>B. Jackson, T. Somerville, C. Taylor, G. Tudor, C. Booth</i>	648
185	Epidermal growth factor receptor (EGFR) gene amplification is not the cause of protein overexpression in penile carcinoma <i>A.M.T. Silva, J.I. Neves, I.W. Cunha, R.M. Rocha, G.C. Guimarães, A. Cubilla, A. Lopes, F.A. Soares</i>	649
186	Multiparameter PET imaging for assessing risk/outcome in sarcoma <i>J.F. Eary, J.M. Link, E.U. Conrad, M. Muzi, F. O'Sullivan, K.A. Krohn</i>	650
187	Pharmacodynamic evaluation of pCDC2 and Wee1 signature as biomarkers of target engagement for the Wee1 tyrosine kinase inhibitor MK-1775 <i>J.D. Cheng, R. Tibes, J.H. Schellens, G.I. Shapiro, A.C. Pavlick, A.M. Oza, Y. Xu, Y. Song, R.L.H. Lam, T. Demuth</i>	651

Chemoprevention

Poster board	Abstract number
188	The p53 pathway as a molecular target for the suppressive chemopreventive action of the histone deacetylase inhibitor tributyrin in rat hepatocarcinogenesis <i>F. Salvador Moreno, M.A. Horst, R. Pierri, A. de Conti, R. Heidor, J.F. Ortega, S.A.R. Paiva, T.P. Ong</i>
189	Evaluation of strychnine, a plant alkaloid for in vitro anti-angiogenesis, apoptosis and antioxidant potential in MCF-7 cancer cells <i>S. Saraswati, R. Mathur, S.S. Agrawal</i>

Hormonal agents

Poster board	Abstract number
190	Predictive value of a dextromethorphan phenotyping test for endoxifen exposure <i>A.J. de Graan, S.F. Teunissen, F.Y. de Vos, W.J. Loos, R.H. van Schaik, F.E. de Jongh, C. Seynaeve, J. Verweij, J.H. Beijnen, R.H. Mathijssen</i>
191	Preliminary report of efficacy of abiraterone acetate in patients with estrogen (ER) or androgen receptor (AR) positive, advanced breast carcinoma resistant to standard endocrine therapies <i>B. Basu, J. Ang, M. Blanco, M. Dowsett, J. Spicer, A. Tutt, S. Johnston, S. Wan, J. De Bono, C. Swanton</i>
192	Suppression of testosterone release by chronic administration of investigational novel metastatin analogues in male dogs and monkeys, and in healthy male volunteers <i>A. Tanaka, H. Matsui, T. Asami, N. Nishizawa, C. Kitada, T. Ohtaki, D. MacLean, M. Kusaka</i>

- 193 Anti-tumor growth effect of TAK-683, a metastatin analogue, in preclinical androgen-dependent prostate cancer models 657
H. Matsui, T. Masaki, Y. Akinaga, A. Kiba, D. Nakata, A. Tanaka, T. Watanabe, T. Ohtaki, M. Kusaka

Immune system

- | | | Abstract number |
|-----|--|-----------------|
| 194 | Prevalence, phenotype and prognostic significance of IL-17-producing cells infiltrating human colorectal cancers
<i>F. Amicarella, I. Zlobec, M.G. Muraro, J. Han, X. Huber, M. Zuber, D. Oertli, A. Lugli, G.C. Spagnoli, G. Iezzi</i> | 658 |
| 195 | A novel mechanism of action of platinum-drugs: breaking STAT6-mediated suppression of immune responses against cancer
<i>W. Lesterhuis, C.J.A. Punt, D. Eleveld-Trancikova, B.J.H. Jansen, C.M.L. Van Herpen, J.H. Kaanders, J.H.J.M. Van Krieken, G.J. Adema, C.G. Figdor, I.J.M. De Vries</i> | 659 |
| 196 | Discovery of a novel series of indoleamine 2,3-dioxygenase 2 (IDO2) selective inhibitors for probing IDO2 function in cancer
<i>X. Liu, G. Yang, Q. Wang, L. Leffet, K. Katiyar, P. Waeltz, T. Burns, A. Combs, R. Newton, P. Scherle</i> | 660 |
| 197 | A pharmacokinetic, pharmacodynamic and electrocardiographic study of L-MTP-PE in healthy volunteers
<i>K. Venkatakrishnan, W.G. Kramer, T. Synold, D.B. Goodman, C. Oliva</i> | 661 |
| 198 | Neuropilin 2 expression on T CD4+ lymphocytes phenotypic study
<i>E. Viel, C. Grandclément, C. Vauchy, X. Pivot, C. Borg</i> | 662 |
| 199 | Intratumoral and serum interleukin-4 levels in prostate adenocarcinoma
<i>R. Goldstein, J. Brown, O. Agbaje, N. Ali, G. Muir, A. Chandra, J. Morris, J. Maher, S. Burbridge</i> | 663 |